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CHAPTER 1 
GENERAL INTRODUCTION AND OUTLINE OF THE STUDY 
GENERAL INTRODUCTION 
Lipoproteins serve as a means of transport for water-insoluble lipids 
in plasma. In these particles a hydrophobic core, consisting of tri­
glycerides and cholesterolesters is surrounded by a hydrophilic sur­
face layer of phospholipids and apolipoproteins. By ultracentrifuga-
tion several lipoproteins can be discriminated according to differen­
ces in density: chylomicrons, very low density lipoproteins (VLDL), 
intermediate density lipoproteins (IDL), low-density lipoproteins 
(LDL) and high-density lipoproteins (HDL). In particular IDL (or rem­
nants) and LDL are known to contribute to the pathogenesis of athero­
sclerotic disease (1). The apolipoproteins are involved in the confir­
mation (apo A-I and apo B) and in the transcellular transport of lipo­
proteins (apo A-I, apo В and apo E) or serve as a co-factor for lipo­
lytic enzymes (apo A-I and apo C-II). Since the metabolism of remnants 
is mainly determined by apo E (1), the role of this protein as a risk 
factor for premature atherosclerotic disease and the influence of its 
isoproteins on lipoprotein metabolism was the object of this thesis. 
Apolipoprotein E was first described by Shore and Shore in 1973, at 
that time named arginine-rich protein (2). Thia glycoprotein has a 
molecular weight of approximately 34,000 daltons and consists of 299 
amino acid residues (3). Apo E is an important surface component of 
remnants of chylomicrons and VLDL and of a special subclass of HDL, 
which is induced by high cholesterol diets, called HDLc (4). Because 
apo E is the primary ligand for the binding of these particles by spe­
cific lipoprotein receptors (5), its role in the catabolism of chol­
esterol-rich lipoproteins and in the reverse cholesterol transport 
(HDLc) appears to be of crucial importance (4). The synthesis of apo E 
takes place predominantly in the liver (6) and is under the control of 
three co-dominant alleles on one gene locus (7). Meanwhile, the nu­
cleotide sequence of the apo E gene, which has been localized on chro­
mosome 19 (8), has been completely elucidated (9). 
In consequence of the genetic polymorphism three major apo E isoforms 
are known, designated E-2, E-3 and E-4 (10). These isoforms can be se­
parated by isoelectric focusing (11), whereby apo E-2 is the most 
acidic and apo E-4 the most basic protein (Fig 1). 
With this technique also some minor bands are obtained. However, by 
two-dimensional isoelectric focusing it was shown that these bands 
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Fig. 1 Isoelectr ic focusi ng gels of VLDL apolipoprotei 
were the result of post-translational addition of one or more nega­
tively charged sialic acid residues to the major isoforms (7). Amino 
acid analysis and sequencing of the major isoforms have revealed that 
a single amino acid substitution at two sites of the molecule (residue 
112 and 158) accounts for the observed charge differences between apo 
E-3 as the parent isoform on the one hand and apo E-2 and E-4 on the 
other (3,12) (Table 1). 
Table 1 Molecular heterogeneity of apo E isoproteins and apo Β,Ε 
receptor binding 
site 112 site 158 Β,Ε receptor binding 
apo E-2 cys cys 
apo E-3 cys arg + 
apo E-4 arg arg + 
Apo E-3 has one residue of cysteine and one of arginine at positions 
112 and 158, respectively. In apo E-2 a residue of cysteine is substi­
tuted for arginine at site 158, whereas in apo E-4 a residue of argi­
nine is substituted for cysteine at site 112. These so called amino 
acid interchanges (12) are thought to be the result of point mutations 
within the parent ε3 allele. In the last years also other uncommon 
mutants have been described, such as apo E Bethesda (13), apo E-1 
(14), apo E-3 Leiden (15), apo E-5 (16) and apo E-Suita (17). 
Based on the current genetic model of apo E and in concordance with 
the presence of two gene pairs in human cells, six apo E phenotypes 
can be identified with isoelectric focusing of VLDL apollpoproteins 
(18): the homozygous phenotypes E3/3, E4/4 and E2/2 and the heterozy­
gous phenotype E4/3, E3/2 and E4/2 (Fig 1). In the Western population 
apo E phenotypes E3/3 (55%), E4/3 {25%) and E3/2 (15S) occur most fre­
quently, because of the high prevalence of the parent ε3 allele (18). 
One of the three rare phenotypes, phenotype E2/2 (IS), is accompanied 
by a disturbance in the removal of lipoprotein remnants (ß-VLDL) 
(11). In vitro binding studies on fibroblasts have indicated that the 
apo E-2 in subjects with the E2/2 phenotype exhibits an abnormal 
interaction with the lipoprotein receptors (19). The presence of an 
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uncharged arginine residue at site 158 in the apo E receptor binding 
region seems to be responsible for the binding defect (3). Besides 
this most prevailing E-2 variant, two other structural variants of apo 
E-2 have been described: E-2 (Argms -»• Cys) (20) and E-2 (Lysj^ ·* 
Gin) (21). These variants all have in common the absence of a posi-
tively charged aminoacid residue in the receptor binding region of apo 
E, but they display differences in the degree of the binding defect 
(20). Nevertheless, in subjects with these variants a similar defect 
in the removal of remnants was observed as in subjects with' the common 
form of apo E-2 (22). 
In spite of the defect in the removal of remnant particles, more than 
95% of subjects with the E2/2 phenotype is normolipidemic and have 
even decreased low density lipoprotein (LDL) concentrations (18). The 
remaining 1-5Ä of E2/2 individuals are hyperlipidemic and have 
Familial Type III hyperlipoproteinemia (or familial dysbetalipopro-
teinemia) (23), which was previously called broad-beta-disease. This 
autosomal recessive inherited disorder of lipoprotein metabolism has a 
multifactorial origin. In addition to homozygosity for the ε2 allele, 
the production of VLDL is largely increased in these patients, because 
of the simultaneous presence of other conditions such as genetic forms 
of hyperlipidemia or diabetes mellitus. Furthermore, age, sex, hor­
monal and nutritional status are important factors (24-26). Clinical­
ly, this disorder is characterized by increased levels of serum chol­
esterol and triglycerides and by the presence of deposits of ß-VLDL in 
the palmar creases (xanthoma striata palmaria) and on the elbows, 
knees, buttocks and hands (tubero-eruptive xanthomas) (26,27). The in-
creased levels of remnants, which are enriched in cholesterol and apo 
E, predispose Type III patients for premature atherosclerotic disease 
of the coronary as well as the peripheral vascular system (26,27), in 
spite of low levels of atherogenic LDL. 
The pioneering work by Utermann and co-workers (11,24,28) has contri-
buted much to our current knowledge about the genetic background in 
Type III hyperlipoproteinemia and more generally on the role of the 
apo E isoforms in lipoprotein metabolism. In their studies they raised 
the possibility, that normolipidemic E-2 homozygous and also some E-2 
heterozygous subjects could have an increased atherosclerotic risk 
like in Type III patients, because of a (partial) removal effect of 
lipoprotein remnants. This hypothesis was the starting point of the 
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investigations, presented in this thesis. 
OUTLINE OF THE STUDY 
In Type III hyperlipoproteinemia the removal of remnants was found to 
be delayed, due to the abnormal functioning apo E isoprotein E-2 
(23). The atherogenicity of remnants has been clearly demonstrated in 
this disorder by the high incidence of atherosclerotic complications 
of the coronary as well as the peripheral arteries (26,27). 
Likewise normolipidemic E-2 homozygotes and possibly also some E-2 
heterozygous subjects have increased amounts of remnants, so that it 
may be questioned, whether they are more at risk for atherosclerosis 
than subjects with the other apo E phenotypes. 
Therefore, apo E phenotypes were determined in patients with angiogra-
phically proven coronary and peripheral artery disease and compared to 
controls without symptoms of vascular disease, matched for several 
known non-lipid risk factors (Chapter 2 and 3). Various lipid and 
lipoprotein parameters were measured as well as the concentration of 
remnants in order to study their relationship to the apo E phenotypes 
and the risk for atherosclerosis. In addition, logistic regression of 
these parameters was performed to find out a set of variables with a 
good predictive power to coronary and peripheral artery disease, res-
pectively. 
Recently the pathogenesis of Familial Hypercholesterolemia and Type 
III hyperlipoproteinemia has been elucidated. However, much remains to 
be learned about possible pathogenetic factors in the most common 
forms of hyperlipidemia, i.e. polygenic hypercholesterolemia (Type II) 
and hypertriglyceridemia (Type IV and Type V). In order to investi-
gate whether the polymorphism of apo E is associated with certain 
forms of hyperlipidemia, patients with known forms of hyperlipopro-
teinemia were screened for their apo E phenotype (Chapter 4). Further-
more, we studied the relationship between the apo E phenotype end the 
lipoprotein composition in these subjects. 
To learn more about a possible role of the apo E polymorphism on the 
metabolism of chylomicron and VLDL-remnants in the normolipidemic 
state, three different dietary studies were performed in healthy 
volunteers with various apo E phenotypes. The rationale behind these 
16 
experiments was, that especially in E-2 heterozygous subjects a (par­
tial) removal defect of remnants may only come to expression after 
challenging the lipoprotein receptor system with increased amounts of 
remnants. 
- The metabolism of chylomicron remnants was studied after an oral fat 
load with cream, to which retinyl palmitate was added as a marker of 
chylomicrons and their remnants (Chapter 5). 
- The metabolism of especially VLDL remnants was investigated by a 
high carbohydrate (low fat) diet with an additional amount of alcohol, 
which is known to induce the synthesis of VLDL (Chapter 6). 
- The metabolism of both chylomicron and VLDL remnants and the other 
lipoproteins was studied, while the volunteers were on a cholesterol-
rich diet during θ days (Chapter 7). 
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CHAPTER 2 
THE APO E POLYMORPHISM AND HYPERLIPOPROTEINEMIA IN 
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A.J. Hoitsma*, Ph. van Eiteren**, and A. van 't Laar. 
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SUMMARY 
The apolipoprotein E phenotype and serum lipid and (apo)lipoprotein 
levels were determined in patients younger than age 65 with angiogra-
phically defined coronary artery disease (CAD; n=145) and in controls 
without signs of vascular disease (n=153). In both groups a similar 
distribution of the various apo E phenotypes was observed. Most fre­
quent were the phenotypes E3/3 (55.9% in CAD vs 47.1% in controls), 
E4/3 (29.0 vs 30.П) and E3/2 (10.3 vs 15.7%). The phenotypes E4/4 
(1.4 vs 4.6%), E2/2 (2.1 vs 1.3«) and E4/2 (1.4 vs 1.3«) were rare. 
There were relatively more men than women in the CAD group (B4.1 vs 
15.9«) compared to the control group (65.4 vs 34.6«). The mean levels 
of very low density plus intermediate density lipoprotein (VLDL+IDL)-
cholesterol and triglycerides, high density lipoprotein (HDL) and low 
density lipoprotein (LDL) cholesterol, apoproteins E, A-I, A-II, serum 
apo B, VLDL+IDL apo В and LDL apo В in male CAD patients differed sig­
nificantly from the corresponding averages for matched male controls. 
By a stepwise logistic regression procedure a high predictive power 
for CAD was observed, when LDL-apo B, HDL-cholesterol, apo A-I and 
cholesterol/apo В were put together in one model. Furthermore, the 
presence of apo E-2 was associated with higher concentrations of serum 
triglycerides, VLDL+IDL-cholesterol, apo E and the ratio VLDL+IDL-
cholesterol/serum triglycerides and a lower concentration serum chol­
esterol and LDL-cholesterol. E-4 was associated with higher LDL-chol-
esterol and lower apo E levels in comparison to the total means of 
each variable. 
Hyperlipoproteinemia (HLP) occurred more frequently in male CAD 
patients than in controls (57 vs 2B«). All E-2 heterozygous males with 
HLP had Type IV. In E-2 heterozygous CAD patients a higher incidence 
for Type IV was observed than in patients with other apo E phenotypes 
and E-2 heterozygous controls. These CAD patients showed higher VLDL+ 
IDL-lipid levels, a lower HDL-cholesterol, but similar LDL-cholesterol 
levels as in their controls. 
It is concluded that only in the presence of hyperlipoproteinemia the 
apo E polymorphism is of importance in the development of CAD. Parti­
cularly homozygosity and heterozygosity for apo E-2 seem to increase 
the risk for CAD in association with Type III and Type IV hyperlipo­
proteinemia. 
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INTRODUCTION 
Abundant evidence has emerged in recent years about the major role of 
apolipoprotein (apo) E in lipoprotein metabolism and cholesterol 
transport (1). As a surface constituent of remnants of chylomicrons 
and very low density lipoproteins (VLDL), apo E is recognized by the 
hepatic and fibroblast apo E and B,E receptors (2,3). Studies by 
Utermann et al. (4) and Zannis et al. (5) demonstrated the existence 
of three apo E isoforms (E-2, E-3 and E-4), which are genetically 
determined by three co-dominant alleles. The isoforms E-2 and E-4 can 
be distinguished from the parent isoform E-3 by isoelectric focusing 
of VLDL apoproteins on account of charge differences, caused by a 
different number of cysteine residues between the isoforms (6). Based 
on this oolymorphism six apo E phenotypes can be identified. Most 
common are E3/3 (55%), E4/3 (2558) and E3/2 (15S), because e3 is the 
most frequent allele in the general population (5,7,8,9). The pheno­
types E4/4, E4/2 and E2/2, which are derived from the mutant alleles 
ε2 and ε4, comprise together only about 5Й. More than 90% of the 
patients with Type III hyperlipoproteinemia (HLP) is homozygous for 
the E-2 isoform (E2/2), which is defective in binding with the lipo­
protein receptors (2,3). In this inherited disorder there is an accu­
mulation of remnants and early atherosclerosis (10). However, about 
96-99% of E2/2 subjects is normolipidemic so that other factors, which 
increase the VLDL production are required for the development of Type 
III HLP. Nevertheless, there is evidence that also normolipidemic E2/2 
subjects have a defective removal of remnants (11-14). 
Several studies have indicated, that the apo E gene contributes to the 
variation of serum lipid and lipoprotein levels in the general popula­
tion (9,15-17). When present in combination with hyperlipidemia, the 
e2 allele is usually associated with hypertriglyceridemia, and the ε4 
allele with hypercholesterolemia (8,IB,19). Therefore, the apo E poly­
morphism might have implications for the risk of premature atheroscle­
rosis. Till now, investigations in patients with coronary artery dis­
ease have not led to definite conclusions (7,20,21). This study was 
undertaken to determine possible influences of the apo E polymorphism 
on coronary artery disease taking other known risk factors into 
account. 
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MATERIALS AND METHODS 
Study protocol 
The study was carried out in patients who were referred to our hospi­
tal in a 3 year period (1983-1986). Patients with suspected or known 
coronary artery disease (CAD) were selected before undergoing coronary 
angiography (Judkin technique). Criteria for exclusion were: age older 
than 65 years, hypertension and diabetes mellitus. At least one steno­
sis of more than ЗОХ on angiography was required for definitive inclu­
sion. The angiograms were reviewed by cardiologists who had no prior 
knowledge of the lipoprotein profiles or apo E phenotypes. A control 
group was recruited from clinic patients without cardiovascular com­
plaints or signs of atherosclerotic disease. This control group was 
matched to the CAD group with regard to age, relative body weight and 
smoking habits. In total, 153 controls and 145 CAD patients were in­
cluded in the study. Blood samples were collected by venepuncture into 
vacutainer tubes after an 11-hrs overnight fast. 
Analysis of lipoproteins and apoproteins 
Serum was separated within 3 hrs after drawing the blood by centrifu-
gation at 2000xg for 15 min. The density of 5 ml of serum was raised 
to 1.019 g/ml by the addition of D2O (d=1.10 g/ml). VLDL+IDL were iso­
lated by ultracentrifugation for 16 hrs at 40,000 rpm (16B,000xg) in a 
I.E.C. B-60 fixed angle rotor no. 468 (Damon I.E.C., Needham Heights, 
Mass., U.S.A.)(14). Heparin sepharose chromatography was performed on 
commercially available columns (LipotypeTM, Biolab, Amersfoort, The 
Netherlands) (14,22). The amount of cholesterol in the heparin bound 
fraction was taken as an estimate of the lipoprotein remnant concen­
tration. HDL-cholesterol was determined in whole serum by the poly-
ethylene-glycol 6000 method (23). LDL-cholesterol was calculated by 
subtracting VLDL+IDL-cholesterol and HDL-cholesterol from total serum 
cholesterol. Serum lipids and lipoprotein lipids were determined en-
zymatically using a centrifugal analyzer (multistat III). Subjects 
were considered hyperlipidemic, when serum triglyceride levels were 
above 2.20 mmol/L and/or cholesterol levels exceeded 7.20 mmol/L. 
The apoprotein E phenotypes were determined by one-dimensional iso­
electric focusing of the VLDL apoproteins and subsequent densitometric 
scanning (24). Apoproteins were determined in quadruplicate by radial 
immunodiffusion in 0.8% agarose in barbital buffer, pH=8.6 (25). Mono-
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specific antibodies against these apolipoproteins, purified by column 
chromatography, if necessary followed by preparative isoelectric 
focusing, were raised in rabbits (apo A-I, A-II and B) and in a sheep 
(apo E). Apo A-I, A-II and E were determined in whole serum. Apo θ was 
determined in whole serum as well as in the d<1.019 g/ml and the 
d>1.019 g/ml fractions. 
STATISTICAL ANALYSIS 
Differences in values of lipids, lipoproteins and apoproteins between 
CAD and controls and between the various apo E phenotype groups were 
statistically analyzed by means of student's two sample test or by the 
t-test of Welch in case of too large differences of sample variances. 
Ρ values less than 5S were considered significant. A stepwise logistic 
regression procedure ("Logist") was used to trace significant lipid, 
lipoprotein and apolipoprotein risk factors for CAD. Variables were 
admitted to the logistic regression if their contribution to the pre­
diction of the dependent variable was significant (p<0.05) according 
to the appropriate X2-test. The same procedure was used to determine 
if levels of serum lipids, lipoproteins and apoproteins were related 
to the presence or absence of the apo E-2 and apo E-4 isoforms. Each 
of these independent variables (lipids, lipoproteins, apoproteins and 
ratios) were studied in separate models to look for a significant re­
lation with these isoforms. 
RESULTS 
Distribution of Apo E phenotypea 
The apo E phenotype frequencies in the CAD and control groups are 
summarized in Table 1. As the CAD group comprised relatively more 
males (84.1 vs 65.4%), the values for both sexes are also given sepa­
rately. There were no significant differences in apo E phenotype dis­
tribution between CAD patients and controls. 
The presentation of the results in the next two sections are confined 
to those of the males, because of the difference in the distribution 
of sexes between the CAD and control group and the low number of 
women. 
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Table 1 Apo E phenotypes in controls and Coronary Artery Disease 
(CAD) 
CONTROLS CAD 
M+f M F M+f M F 
(n=153) (nrlOO) (n=53) (n=145) (n=122) (n=23) 
Phenotypes % % % % % % 
E2/2 
E3/2 
E3/3 
E4/2 
E4/3 
E4A 
1.3 
15.7 
47.1 
1.3 
30.1 
4.6 
1.0 
15.0 
46.0 
2.0 
30.0 
6.0 
1.9 
17.0 
49.1 
-
30.2 
1.9 
2.1 
10.3 
55.9 
1.4 
29.0 
1.4 
2.5 
10.7 
56.6 
1.6 
27.9 
0.Θ 
-
Θ.7 
52.2 
-
34.8 
1.4 
Comparison CAD vs controls by X¿ test for contingency table 
Males + females (M-fF) 
Males (M) 
Females (F) 
p=0.35 
p=0.19 
p=0.79 
Characteristics and serui lipids, lipoproteins and apoproteins of «ale 
CAD patients and controls 
The male CAD patients and controls were comparable with regard to age, 
relative weight and smoking habits (Table 2). Significant differences 
between the groups were found in all studied biochemical parameters, 
except heparin-unbound triglycerides and the ratio cholesterol/total 
apo B. 
Subsequently, a comparison was made between the most frequent apo E 
phenotypes E3/2, E3/3 and E4/3 in both groups with regard to their 
effects on the levels of serum lipids, lipoproteins and apoproteins 
(Table 3). In the control group the serum lipid and lipoprotein con-
centrations did not differ significantly in any of the apo E phenotype 
groups. In the E3/2 CAD patients serum cholesterol (p<0.05) and LDL-
cholesterol (p<0.001) were lower than in the E3/3 patients. 
2Θ 
Table 2 Characteristics and serum lipids, lipoproteins (mmol/l) and 
apoproteins (mg/1) of male controls and CAD patients, matched 
for age, relative weight and smoking 
Age ( y r s ) 
R e l a t i v e w e i g h t * 
Smoking + 
c h o l e s t e r o l t 
t r i g l y c e r i d e s 
VLDL+IDL-chol 
VLDL+IDL-TG 
HDL-chol 
LDL-chol 
Hepann-bound 
c h o l 
TG 
Heparm-unbound 
chol 
TG 
Apo L 
Apo A-I 
Apo A - I I 
T o t a l apo В 
VLDL+IDL-apo В 
LDL-apo В 
VLDL+IDL-chol/serun TG 
LDL-chol/HDL-chol 
apo A-I/apo В 
chol/apo В 
CONTROLS 
(n=100) 
50.7+ 7.В 
115.1+12.θ 
2.4+ 1.2 
6.16+1.10 
2.05+1.75 
1.16+0.73 
1.41+1.47 
1.06+0.28 
3.94+0.99 
0.72+0.36 
0.58+0.30 
0.36+0.45 
0.71+1.33 
74+28 
1568+276 
515+101 
1504+378 
152+63 
1320+373 
0.60+0.17 
3.94+1.33 
1.12+0.36 
0.004+0.001 
CAD 
(π=122) 
51.7+ 7.7 
117.4+12.2 
2.6+ 1.1 
6.Θ9+1.54 
2.53+1.52 
1.67+1.17 
1.84+1.25 
0.89+0.22 
4.33+1.20 
1.03+0.68 
0.77+0.37 
0.56+0.57 
0.84+0.83 
85+38 
1399+282 
480+102 
1680+463 
184+86 
1524+489 
0.66+0.21 
5.15+1.98 
0.90+0.33 
0.004+0.001 
Ρ 
NS 
NS 
NS 
<0.0001 
0.032 
0.0002 
0.019 
<0.0001 
0.010 
<0.0001 
<0.00Ü1 
0.005 
NS 
0.015 
<0.0001 
0.010 
0.003 
0.003 
0.0007 
0.022 
<0.0001 
<0.0001 
NS 
Values are mean + SD 
CAD = coronary artery disease 
•Metropolitan Life Insurance Company Tables 1983 
'''Each subject was scored for smoking habits: 1 = not smoking; 2 = less 
than 10, 3 = 10-20 and 4 = 20 or more cigarettes per day 
tchol = cholesterol; TG = triglycerides 
Conversion factors for cholesterol and triglycerides to mg/dl 
respectively: 38.7 and 88.0 
29 
Furthermore, they had elevated serum triglycerides and 
VLDL+IDL-cholesterol levels (p<0.05) and decreased LDL-cholesterol 
levels (p<0.001) compared with the E4/3 patients. The ratio 
LDL-cholesterol/HDL-cholesterol was significantly higher in the E3/3 
and E4/3 subjects of both groups compered with the E-2 heterozygous 
subjects. The effects of the apo E polymorphism on the apolipoproteins 
were similar in both the control and the CAD group. In all E4/3 
subjects apo E levels were lower than in the E3/2 subjects; in the CAD 
group only, apo E levels were lower in E4/3 subjects than in both E3/2 
and E3/3 subjects (p<0.05). The E-2 heterozygous controls and CAD 
patients showed the highest levels of apo E, but had lower levels of 
total apo В (p<0.05 vs E3/3 subjects and p<0.01 vs E4/3 subjects of 
both controls and CAD) and LDL apo В (p<0.05 vs ЕЭ/3 and E4/3 controls 
and E3/3 CAD; p<0.01 vs E4/3 CAD). Moreover, a comparison was made 
between the E3/2 CAD patients and their controls. The serum 
triglycerides, in contrast to the serum cholesterol, were 
significantly elevated in the E3/2 CAD patients (p<0.01). This was 
also the case for the VLDL lipids (p<0.01), heparin bound and unbound 
cholesterol (p<0.05) and the ratio LDL-cholesterol/HDL-cholesterol 
(p<0.05). On the other hand HDL-cholesterol (p<0.001), apo A-I 
(p<0.05), apo A-II (p<0.01) and apo A-I/total apo В (p<0.001) were 
decreased in the E3/2 patients compared to the E3/2 controls. 
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Table 3 Serum lipids, lipoproteins (mmol/L) and apolipoprotelns (mg/L) in male controls and CAD patients 
with apo E phenotypes E3/2, E3/3 and E4/3 (mean + SD). 
CONTROLS 
E3/2 E3/3 E4/3 
(n=15) (n=46) (n=30) 
Cholesterol 5.74+1.16 6.22+1.11 6.30+0.97 
Triglycerides 1.71+0.64 2.11+1.35 2.14+2.60 
VLDL+IDL-chol 1.05+0.37 1.18+0.66 1.13+0.81 
VLDL+IDL-TG 1.07+0.48 1.46+1.09 1.50+2.32 
HDL-chol 1.19+0.28 1.04+0.28 1.03+0.25 
LDL-chol 3.51+1.03 4.00+0.98 4.18+0.87 
Hep. bound chol 0.71+0.24 0.74+0.32 0.66+0.35 
Hep. unbound chol 0.27+0.15 0.36+0.39 0.39^0.61 
apo E 81+20 76+23 64+27* 
apo A-I 1602+284 1568+293 1589+263 
apo A-II 540+106 511+93 516+107 
Total apo В 1298+255 1528+353* 1622+387+ 
LDL-apo В 1158+247 1375+361* 1362+387* 
VLDL+IDL-chol/serum TG 0.64+0.21 0.59+0.16 0.58+0.13 
LDL-chol/HDL-chol 3.05+0.84 4.03+1.17+ 4.02+1.33+ 
apo A-I/total apo В 1.27+0.31 1.09+0.30 1.03+0.29* 
CAD = coronary artery disease 
chol = cholesterol; TG = triglycerides 
(For conversion factors see table 2) 
*p<0.051 +p<0.01 vs E3/2 controls 
*p<0.05 Vs E3/3 controls 
CAD 
E3/2 E 3/3 E4/3 
(n=13) (n=69) (n=34) 
6.08+1.22 6.9Θ+1.65* 6.77+1.08 
2.97+1.29* 2.47+1.72 2.22+0.82* 
1.94+1.1611 1.56+0.89 1.34+0.50* 
2.15+1.IS' 1.74+1.38 1.68+0.80 
0.85+0.1611 0.89+0.23 0.89+0.23 
3.29+0.79 4.53+1.24+ 4.53+0.87+ 
1.04+0.41& 1.02+0.71 0.88+0.30 
0.81+0.78* 0.51+0.45 0.39+0.22 
104+41 86+36 67+16+* 
1333+287* 1405+286 1384+71 
425+7θ1, 489+107 467+83 
1394+298 1718+510* 1757+391+ 
1241+317 1565+535* 1611+353+ 
0.64+0.13 0.66+0.19 0.61+0.13 
3.91+0.87* 5.37+1.92+ 5.53+2.15+ 
0.96+0.16* 0.90+0.35 0.B4+0.29 
*p<0.05, tp<0.01 vs E3/2 CAD 
*p<0.05 vs E3/3 CAD 
4p<0 05, 1'p<0.01 vs E3/2 controls 
Hyperlipoproteinemia (HLP) and the apo E polymorphism in male CAD 
patients and controls (Table 4) 
Hyperlipoproteinemia (HLP) was found in 28л of the controls and in 57% 
of the CAD patients (p<0.05). Type IIA was equally present in both 
groups (BS and 10% respectively). On the other hand Type IIB was ob­
viously more frequent in the CAD group (13S vs IS; p<0.05). The three 
CAD subjects with apo E phenotype E2/2 (Table 1) all had Type III 
HLP. The only control subject with this phenotype was normolipidemic. 
Type IV was more frequently seen in the CAD group (33% з 1В%; 
p<0.05). Both in CAD and controls Type V HLP occurred only in one sub­
ject. 
In each group 3 phenotype classes were formed: the E3/24E4/2 ( ε2 
allele present), the E3/3 and the Е4/ЗчЕ4/4 (εΑ allele present) 
class. HLP was in all phenotype classes of the CAD group more frequent 
than in those of the control group. Type IIA and IIB did neither occur 
in E-2 heterozygous controls nor in E-2 heterozygous CAD patients. In 
case of hyperlipoproteinemia these subjects all had Type IV HLP. More­
over, Type IV was more frequent in E-2 heterozygous CAD patients com­
pared to controls with this phenotype (p=0.01) and also in comparison 
with CAD patients in the E3/3 and E4/3-fE4/4 classes (p<0.01). The E3/3 
and E4/3-fE4/4 class of both groups were not associated with the pre­
sence of either Type IIA and Type IIB or Type IV HLP. 
32 
Table 4 Occurrence of hyperlipoproteinemia in male coronary artery disease in relation to the apo E 
phenotypes (except E2/2) compared to controls 
CONTROLS 
E3/2 + E4/2 E3/3 E4/3 + E4/4 
HLP η (S) η (%) η (Ж) 
IIA - 4 (9) 4 (11) 
IIB - 1 (2) 
IV 3 (18) 9 (20) 6 (17) 
V - - 1 (3) 
NORMAL 14 (82) 32 (69) 25 (69) 
TOTAL 17 (100) 46 (100) 36 (100) 
TOTAL 
η (%) 
8 ( 8) 
1 ( 1) 
18 (18) 
1 ( 1) 
71 (72) 
99 (100) 
CAD 
E3/2 + E4/2 E3/3 E4/3 + E4/4 
η (.%) η (Я) η (й) 
10 (14) 2 (6) 
9 (13)+ 7 (20)' 
10 (67)*+ 21 (30) 8 (23) 
1 (1) 
5 (33) 28 (11) 18 (51) 
15 (100) 69 (100) (100) 
TOTAL 
η (S) 
12 (10) 
16 (13) 
39 (33) 
1 ( 1) 
51 (43) 
119 (100) 
CAD = coronary artery disease 
HLP = hyperlipoproteinemia; classification according to WHO criteria (Bull. WHO 1970; 43: 891-915) 
* ρ = 0.01 vs E3/2 + E4/2 controls (Fisher exact test) 
+ ρ < 0.01 vs E3/3 and E4/3 + E4/4 CAD respectively 
* ρ < 0.05 vs E3/3 controls 
Up < 0.01 vs E4/3 + E4/4 controls. 
UJ 
4*1 
Stepwise logistic regression analysis 
The (apo)lipoprotein data were further analyzed by a stepwise logistic 
regression procedure to find a model of variables with a high predict­
ive power for CAD (Table 5). It was found that the combination of LDL 
apo B, cholesterol/total apo B, HDL-chol and apo A-I gave a good fit 
in predicting CAD. The probability of success in predicting CAD on the 
basis of this model was approximately 80%. 
Table 5 Logistic regression coefficients (b) + SD of variables with 
the most significant contribution to the prediction of coronary artery 
disease (CAD) 
Variables* b SD Χ Ρ 
LDL apo В 
chol/total apo В 
apo A-I 
HDL-chol 
0.0024 
0.Θ520 
-0.0020 
-2.0924 
0.0005 
0.2230 
0.0006 
0.69Θ7 
27.03 
14.65 
10.37 
8.97 
<0.0001 
0.0001 
0.0013 
0.0027 
Fraction of concordant pairs of predicted probabilities 
and responses: 0.794 
Rank correlation between predicted probability and 
response: 0.596 
•Dependent variable: Control/CAD; Independent variables: Sex, VLDL+IDL-
chol, LDL-chol, HDL-chol, apo E, apo A-I, LDL apo В and 
ratios: VLDL+IDL-chol/serum TG, LDL-chol/HDL-chol and chol/total apo В 
With this method we also studied a possible relationship between the 
apo E polymorphism and the levels of serum lipoproteins and apolipo-
proteins (Table 6). The presence or absence of the apo E isoforms E-2 
and E-4 were taken as dependent variable. Apo E-2 was associated with 
higher levels of serum triglycerides, VLDL+IDL-cholesterol, total apo 
E and the ratio VLDL+ IDL-cholesterol/serum triglycerides and with 
lower levels of serum cholesterol, LDL and VLDL+IDL-cholesterol, com­
pared to the total mean of each variable in all subjects. E-4 was 
associated with lower levels of apo E and a lower ratio of VLDL+IDL-
cholesterol/serum triglycerides and apo A-I/total apo В and higher 
concentrations of LDL-cholesterol and LDL apo B. E-4 did not have sig­
nificant effects on serum triglycerides and cholesterol. 
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Table 6 Logistic regression coefficients (b) +_ SD of independent lipoprotein and apoprotein 
variables with a significant relation to the three apo E isoforms in males and females. 
Variables* E-2 present/absent E-4 present/absent 
a) Serum chol 
Serum TG 
b) VLDL+IDL-chol 
LDL-chol 
c) VLDL+IDL-chol/serun TG 
LDL-chol/HDL-chol 
apo A-I/total apo В 
d) apo E 
LDL-apo В 
b 
-0.3384 
0.2015 
0.440B 
-0.8463 
2.1983 
-0.3714 
0.0279 
-0.0019 
X 
8.55 
4.75 
8.33 
31.42 
Θ.83 
10.63 
NS 
25.87 
20.01 
Ρ 
0.0035 
0.0293 
0.0039 
<0.0001 
0.0030 
0.0011 
<0.0001 
<0.0001 
b 
0.2719 
-1.5408 
-0.8773 
-0.0213 
0.0007 
X 
NS 
NS 
NS 
8.44 
5.54 
NS 
8.62 
15.83 
7.79 
Ρ 
0.0037 
0.01B6 
0.0033 
0.0001 
0.0052 
•Dependent variables: E-2 and E-4 present or absent 
Independent variables: a) Sex, Smoking, Serum cholesterol and triglycerides 
b) Sex, Smoking, VLDL+IDL-chol, LDL-chol and HDL-chol 
c) Sex, Smoking, VLDL+IDL-chol/serum TG, LDL-chol/HDL-chol, apo A-II/total 
apo В and chol/total apo В 
d) Sex, Smoking, apo E, apo A-I, apo A-II, VLDL+IDL-apo В and LDL-apo В 
DISCUSSION 
Apolipoprotein E has an important function in the uptake and catabol-
ism of triglyceride-rich lipoproteins in the liver. In type III hyper-
lipoproteinemia homozygosity for the receptor defective E-2 isoform 
and VLDL overproduction gives rise to strongly elevated concentrations 
of remnants of intestinal and hepatic origine (26), leading to prema-
ture atherosclerotic disease. Another isoform of apo E, apo E-4, 
appears to have a different metabolism than the parent E-3 isoform 
(27) and has been associated with hypercholesterolemia (8,18,19). 
Ghiselli et al. reported an association between E-4 and type V hyper-
lipoproteinemia (28). However, this was not confirmed by Stuyt et al. 
(29). The central role of apo E in lipoprotein metabolism raises the 
possibility of a relation between the apo E polymorphism and the risk 
for atherosclerosis. From our case-control study, however, we conclude 
that the distribution of the apo E phenotypes in patients with corona-
ry artery disease (CAD) is similar as in controls without signs of 
vascular disease, who were matched for age, relative weight and 
smoking. These findings are in agreement with those of Menzel et al. 
(7) and Utermann et al. (21), but disagree with Cumming et al. (20), 
who found a relatively higher proportion of CAD subjects with apo E 
phenotype E4/3. In contrast to others (20,30) we did not find any 
difference in mean age between the various apo E phenotypes in CAD 
patients (results not shown). This can be explained by the fact that 
we studied angiography patients and not survivors of myocardial in-
farction. On the other hand there were many significant differences in 
various lipid and lipoprotein and apoprotein concentrations between 
the CAD and controls (Table 2). Only the results of the males were 
presented, first because 85S of the CAD group (n=122) were male and 
only a small number (n=23) female and second because the male CAD 
patients were matched to male controls with regard to age, relative 
weight and smoking habits. Lipid risk factors are strongly underlined 
in this study because we excluded diabetic and hypertensive patients. 
By multiple logistic regression the combination LDL apo B, chol-
esterol/total apo B, HDL-chol and apo A-I had a high predictive power 
for CAD in comparison with other independent variables that were test-
ed. In general, our results agree well with other angiographic case-
control studies (31-36). 
The apo E polymorphism contributes to some extent to the variability 
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of some of the above-mentioned lipid lipoprotein and apoprotein 
levels. The ε2 allele is associated with elevated VLDL+IDL-cholesterol 
levels and lower total cholesterol, LDL-cholesterol and LDL-apo В 
levels (16,17) whereas the opposite is true for the other allele e4 
(8,16,17). This is confirmed by our study. Furthermore, E2/2 and E3/2 
subjects (except controls) had higher levels of apo E and E4/4 and 4/3 
subjects had lower levels of apo E compared to E-3 homozygous sub­
jects, in agreement with other authors (17,27,37). These effects were 
confirmed by stepwise logistic regression (Table 6). The discrepancy 
between the E-2 heterozygous CAD and control subjects in the apo E 
levels can be explained by the higher triglyceride levels of the 
former. In other words, our results indicate that in case of heterozy­
gosity for apo E-2 this allelic effect on apo E is only present in 
combination with hypertriglyceridemia, because in that situation the 
removal of lipoprotein remnants may become more critical. In case of 
normolipidemia we have shown earlier that after a fat load the clear­
ance of chylomicron remnants is normal in normolipidemic E-2 heterozy­
gotes (14). 
In addition, we studied a possible relationship between the apo E po­
lymorphism and the occurrence of hyperlipidemia. All male E-2 hetero­
zygous subjects (CAD and controls) with hyperlipidemia had a Type IV 
HLP in contrast to subjects with other phenotypes, where other forms 
of HLP did occur. The association of the E-2 heterozygous phenotype 
with hypertriglyceridemia was also documented by others (7,18,38). 
Comparing male controls and CAD patients with these phenotypes, we 
found that E2/2 CAD subjects all had Type III, whereas the only con­
trol subject with E2/2 was normolipidemic; Type IV HLP occurred signi­
ficantly more frequent in E-2 heterozygous CAD patients than in con­
trols (675» vs 18л). Because in E-2 heterozygous CAD patients elevated 
levels for serum triglycerides, VLDL+IDL-cholesterol and VLDL+IDL-tri­
glycerides were found in combination with low LDL-cholesterol levels 
(compared to other phenotypes), we suppose that a partial remnant re­
moval effect, causing elevated VLDL+IDL lipid levels may be an im­
portant causal factor in the development of CAD in these subjects. 
This is supported by the work of Janus et al (39), who found similari­
ties between classical Type III HLP and hyperlipidemic E3/2 and E4/2 
subjects, introducing the terms heterozygous and homozygous Type III 
HLP. In E-2 heterozygous hyperlipidemics they observed a widened pre-ß 
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band with agarose electrophoresis, but lower VLDL lipid levels and a 
lower ratio VLDL/serum triglycerides than in the E-2 homozygotes. 
Atherosclerotic disease was found as frequent as in the classical Type 
H I patients (about ЗОЙ). Kameda et al. (40) described an increased 
incidence of a type of dysbetalipoproteinemia similar to Type III in 
Japanese survivors of myocardial infarction. In this subcategory of 
patients phenotypes E3/2 and 4/2 were found in ЗВЙ compared to 7% in a 
patient group without a widened pre-β band on electrophoresis. Owing 
to different dietary customs in Eastern countries like Japan with a 
high content of carbohydrates, plasma triglyceride levels may be high­
er than in Western Europe (40). This may explain why the E-2 heterozy­
gous phenotypes are relatively frequent in their patients (25S) in 
comparison with their controls (755) and compared to what we and others 
have found (7,20,21). Of interest in this context is the study of 
Tatami et al. (34), who found a relation of IDL-cholesterol with the 
degree and the frequency of angiographically defined CAD, which was 
independent of LDL and HDL-cholesterol. 
In contrast to others (8,18,19) we could not establish a significant 
association between ε4 and HLP Type H A and IIB. 
We conclude that the genetic polymorphism of apo E may contribute to 
the development of CAD, only in combination with hyperlipidemia. Par­
ticularly, this was demonstrated, when homozygosity for apo E-2 was 
associated with Type III and heterozygosity for apo E-2 with Type IV 
hyperlipoproteinemia. 
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SUMMARY 
Apo E phenotypes, serum lipoproteins and apolipoproteins were deter­
mined in 76 patients with angiographically proven peripheral vascular 
disease and compared with 153 controls without signs of atherosclero­
tic disease, matched for age, sex and relative weight. Patients and 
controls exhibited a similar apo E phenotype distribution, but differ­
ed significantly with regard to the concentrations of serum lipids, 
lipoproteins and apolipoproteins, except serum apo E. By stepwise 
logistic regression it appeared that the combination of smoking, LDL-
apo B, apo A-I and VLDL+IDL-cholesterol (in decreasing order of signi-
ficancy) was most powerful in discriminating patients from controls. 
In both groups the apo E polymorphism was found to influence serum and 
LDL-cholesterol levels and the concentrations of apo В and E. In the 
patients heterozygosity for apo E-2 was accompanied in 50% of the 
cases by elevated levels of VLDL+IDL-cholesterol and triglycerides. 
Hypercholesterolemia was more frequently found in patients with apo E 
phenotype E4/3 or E4/4. 
These results suggest, that, although it cannot be considered an inde­
pendent risk factor, in the presence of hyperlipidemia the apo E poly­
morphism affects the concentrations of lipoproteins and may contribute 
in that case to premature peripheral vascular disease. 
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INTRODUCTION 
Apolipoprotein E (apo E) is an essential determinant in the uptake of 
lipoprotein remnants by the hepatic lipoprotein receptors (1,2). In 
man three apo E isoforms (E-2, E-3 and E-4) exist, originating from 
three co-dominant apo E alleles (3,4). Apo E-2 is poorly recognized by 
the hepatic receptors (1,5). Owing to this defective receptor inter­
action subjects with the E2/2 phenotype have elevated concentrations 
of remnants of triglyceride-rich lipoproteins, a condititm designated 
dysbetalipoproteinemia (6). In 1-4S of them additional factors, in­
creasing the production of very low density lipoproteins (7), lead to 
the development of familial type III hyperlipoproteinemia, which is 
strongly associated with premature coronary and peripheral vascular 
disease (8). Binding studies on fibroblasts revealed the same normal 
receptor binding characteristics for apo E-3 and E-4 (9); however, in 
vivo a faster metabolism of radiolabeled apo E-4 in comparison with 
apo E-3 and E-2 was recently demonstrated (10). Previous epidemiologic 
studies indicated already opposite effects of the apo E alleles e2 and 
ε4 on serum lipids and lipoproteins (11-13). Higher triglyceride 
levels were primarily associated with the eZ allele, whereas elevated 
cholesterol levels with the εώ allele (12,13). According to these 
findings the apo E polymorphism may contribute to the clinical course 
of atherosclerotic disease. So far most studies on this issue concern­
ed coronary artery disease (14-16). In the present investigation we 
studied the apo E polymorphism and (apo)lipoproteins in patients with 
angiographically defined peripheral vascular disease and in age and 
sex matched controls. 
MATERIALS AND METHODS 
Study protocol 
Patients not older than 65 yrs., who were referred to our hospital 
with suspected peripheral vascular disease (PVD) and underwent percu­
taneous lumbal aortography, were selected for this study. Criteria for 
inclusion were at least one stenosis of more than 50% in the aorto-
iliacal or femoral traject and absence of hypertension and diabetes. 
The angiograms were judged by a radiologist who was unaware of any la­
boratory parameter. Clinic patients, who were free of cardiovascular 
symptoms, served as control group. Control (n=153) and PVD (n=76) 
group were matched for age and sex, but differed significantly in 
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smoking habits (Table 1). Blood samples were taken before aortography 
(PVD) by venepuncture after an 11-hr overnight fast. 
Table 1 Clinical features and serum lipids in patients with peri-
phi 
Age ( y r s . ) 
Sex (M/F) 
R e l a t i v e Wei 
Smoking''" 
г г а і 
Lght 
v a s c u l a r 
(*)* 
disease (PVD) 
C o n t r o l s 
(n=153) 
50.2+8.2 
100/53 
118.1+15.2 
3.2+0.9 
and c o n t r o l s . 
PVD 
(n=76) 
50.5+9.5 
56/20 
117.0+14.5 
2.3+1.3 
Ρ 
NS 
NS 
NS 
<0.001 
All values are expressed as means + SD. 
•The ratio between actual weight and ideal weight x100S, based on 
Metropolitan Life Insurance Company Height and Weight tables (1983) 
"•"Subjects were scored for smoking: 1=0, 2=1-10, 3=11-20 and 4=more 
than 20 cigarettes per day. 
Analysis of lipoproteins and apoproteins 
Lipoproteins were separated by ultracentri fugation in serum as report­
ed elsewhere (17) after low speed centrifugation of the blood sam­
ples. Heparin-sepharose chromatography was performed according to 
Shelburne and Quarfordt (1Θ) on Lipotype™ columns, which were pur­
chased from Biolab, Amersfoort, the Netherlands (17). The concentra­
tion of heparin bound cholesterol was taken as an estimate of the con­
centration of remnants of triglyceride-rich lipoproteins. Cholesterol 
and triglycerides were determined enzymatically by a centrifugal ana­
lyser (17). Apo E phenotypes were determined after one-dimensional 
isoelectric focusing of the VLDL+IDL apollpoprotelns and densitometric 
scanning (19,20). Apolipoproteins were determined in quadruplicate by 
radial immunodiffusion (21). 
RESULTS 
Clinical features and frequencies of apo E phenotypes 
The PVD and control groups were highly comparable with regard to sex, 
age and relative weight (Table 1). In the PVD group the smoking score 
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was higher than in the controls (p<0.001). No significant differences 
in apo E phenotype frequencies were observed between the PVD and the 
control group (Table 2). This was also the case when only the most 
common phenotypes E3/3, E4/3 and E3/2 were compared. 
Table 2 Frequencies of apo E phenotypes in age and sex matched 
patients with peripheral vascular disease (PVD). 
Controls (n=153) PVD (n=76) 
Phenotypes % % 
E3/3 47.1 55.2 
E4/3 30.1 25.0 
ЕЭ/2 15.7 6.6 
E4/2 1.3 6.6 
E4/4 4.6 6.6 
E2/2 1.3 
NS* 
•X* = 1.702 (DF = 4); p=0.79 for all apo E phenotypes except E2/2 
SeriM lipide, lipoproteins and apolipoproteins 
A comparison was made first between the entire PVD and control groups 
(Table 3) and secondly between corresponding apo E phenotype subcate­
gories in each group (E3/2+E4/2, E3/3 and E4/3+E4/4 respectively; 
Table 4), to investigate a possible role of the apo E polymorphism in 
the variation of serum lipids, lipoproteins and apolipoproteins. Chol­
esterol and triglycerides were higher in the PVD groups (p<0.01 and 
p<0.05 respectively; Table 3). In the PVD group a higher mean LDL-
cholesterol level was observed than in the control group (p<0.05). 
Serum cholesterol and LDL-cholesterol were the lowest in the E3/2+E4/2 
subgroup and the highest in the E4/3-tE4/4 subgroup of the controls as 
well as the PVD group. HDL-cholesterol was in the PVD group lower 
(p<0.001) than in the control group (Table 3), but in each group simi­
lar levels per apo E phenotype subgroup were found (Table 4), except 
in E4/3-tE4/4 controls, who had lower (p<0.05) levels than E-2 hetero­
zygous controls. In the PVD group the mean concentrations of chol­
esterol and triglycerides in the VLDL+IDL, the heparin bound and un-
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Table 3 Concentrations (mean + 50) of serum lipids and lipoproteins 
(mmol/L) and apolipoproteins (mg/L) in controls and patients 
with peripheral vascular disease (PVD). 
Controls PVD ρ 
(n=153) (n=76) 
Cholesterol 
Triglycerides 
VLDL+IDL-chol* 
VLDL+IDL-TG 
LDL-chol 
HDL-chol 
Heparin bound-chol 
Heparin bound-TG 
Heparin unbound-chol 
Heparin unbound-TG 
VLDL+IDL-chol/Serum-TG 
apo E 
apo A-I 
apo A-II 
total apo В 
VLDL+IDL-apo В 
LDL-apo В 
6.10+1.19 
1.82+1.50 
1.05+0.67 
1.20+1.26 
3.92+1.01 
1.15+0.31 
0.69+0.35 
0.52+0.28 
0.30+0.38 
0.57+1.10 
0.59+0.16 
74+28 
1609+295 
512+106 
1464+401 
144+62 
1256+366 
6.67+1.44 
2.26+1.33 
1.43+0.92 
1.60+1.13 
4.28+1.23 
0.97+0.28 
0.90+0.44 
0.69+0.35 
0.46+0.50 
0.74+0.88 
0.64+0.24 
75+25 
1452+315 
459+110 
1689+412 
180+94 
1533+447 
<0.01 
<0.05 
<0.001 
<0.05 
<0.05 
<0.001 
<0.001 
<0.001 
<0.01 
NS 
NS 
NS 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
*Chol = cholesterol (mg/dl = 38.8 χ mmol/L) 
TG = triglycerides (mg/dl = 88.5 χ mmol/L) 
bound fractions (except heparin unbound-tnglycendes) were signifi­
cantly higher than in the control group (Table 3). The VLDL+IDL-chol-
esterol- and triglyceride concentrations were similar in the three 
control subgroups (Table 4), but were elevated in the E3/2+E4/2 sub­
group of the PVD patients in comparison to the other PVD and all con­
trol subgroups. The highest remnant concentrations, represented by the 
hepann-bound cholesterol fraction, were found in the E3/2+4/2 sub­
group of both the controls and PVD patients, however these differences 
were not significant. In general elevated remnant concentrations were 
observed in all apo E phenotype subcategories of the PVD group com-
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Table A Concentrations (mean + SD) of serum lipids and lipoproteins (mmol/L) and apolipoproteins (mg/L) in controls and 
PVD patients according to three apo E phenotype subgroups: E3/2+E4/2, E3/3 and E4/3+E4/4. 
C o n t r o l s 
E3/2+E4/2 E3/3 E4/3+E4/4 
(n=26) (n=72) (n=53) 
C h o l e s t e r o l ( c h o l ) 5.73+1.50 6.16+1.17 6.24+1.02 
T r i g l y c e r i d e s (TG) 1.69+1.00 1.87+1.22 1.83+2.01 
VLDL+IDL-chol 1.11+0.73 1.04+0.63 1.02+0.71 
VLDL+IDL-TG 1.04+0.68 1.24+0.93 1.23+1.74 
LDL-chol 3.40+1.15 3.95+0.97* 4.16+0.85+ 
HDL-chol 1.24+0.31 1.17+0.34 1.08+0.27* 
Heparin bound-chol 0.75+0.43 0.69+0.33 0.64+0.34 
VLDL+IDL-chol/serum TG 0.61+0.17 0.57+0.14 0.59+0.14 
apo E 93+38 75+21+ 6 3 + 1 3 A + 
apo A- I 1653+263 1600+322 1590+260 
apo A - I I 522+114 514+105 501+105 
t o t a l apo В 1193+319 1481+392* 1572+373* 
VLDL+IDL-apo В 141+63 147+61 141+66 
LDL-apo В 1073+290 1280+371+ 1317+365+ 
* p < 0 . 0 5 , V O . 0 1 , ' V o . O O l vs E3/2+E4/2 c o n t r o l s 
Ap<0.001 vs E3/3 c o n t r o l s . 
PVD 
E3/2+E4/2 ЕЗ/3 E4/3+E4/4 
(n=10) (n=42) (n=24) 
6.46+1.78 6.49+1.43 7.08+1.26 
2.73+1.48 2.13+1.34 2.29+1.25 
2.04+1.42" 1.37+0.80* 1.30+0.80 
2.07+1.39" 1.49+1.08 1.61+1.12 
3.45+1.10 4.15+1.15 4.86+1.19 + 
0.97+0.27" 0.98+0.27 0.96+0.33 
1.16+0.52 0.89+0.45 0.80+0.35 
0.71+0.15 0.67+0.29 0.57+0.13* 
99+25 72+26+ 69+16+ 
1367+308" 1474+360 1450+230 
475+118 471+120 432+84 
1528+425" 1689+425 1755+383 
191+94 189+109 159+57 
1376+430 1511+470 1636+403 
* p < 0 . 0 5 , +p<0.01 vs E3/2+E4/2 PVD 
1Ip<0.05 vs E3/2+E4/2 c o n t r o l s 
pared with the corresponding controls, but in the E3/2+4/2 subgroup 
this elevation seemed to be the largest (Table 4 ) . The VLDL+IDL-chol-
esterol/serum-triglycendes ratio was similar in both groups (Table 
3), however, in the E-2 heterozygous PVD patients this ratio was sig­
nificantly higher than in the E4/3+E4/4 patients (Table 4). 
In all apolipoproteins, except apo E, significant differences between 
the two groups were found (Table 3): apo A-I and A-II were lower, 
whereas total apo B, VLDL+IDL apo В were higher. For apo E the highest 
levels were observed in the E3/2 subgroup, intermediate levels in the 
E3/3 and lower levels in the E4/3+4/4 group of both controls and PVD 
(Table 4). Apo A-I was decreased in all PVD subgroups, but only signi­
ficantly in the E3/2+4/2 group compared to the corresponding control 
group. In accordance with the findings for total cholesterol and LDL-
cholesterol, the highest total and LDL-apo В levels were found in the 
E4/3+E4/4 group and the lowest in the E3/2+E4/2 group in the controls 
as well as the PVD patients. In the E3/2+E4/2 PVD patients total apo В 
was significantly higher compared with their controls. VLDL+IDL-apo В 
levels were higher in the PVD subgroups, however no differences were 
found between the apo E phenotype categories in both the control and 
PVD groups. 
Table 5 Logistic regression coefficients (b) +_ SD of independent 
variables with the most significant contribution to the pre­
diction of peripheral vascular disease (PVD) 
Variables* 
Smoking 
LDL apo В 
A-I 
VLDL+IDL-chol 
b 
0.5943 
0.0014 
-0.0016 
0.5574 
SD 
0.1549 
0.0004 
0.0006 
0.216B 
X2 
14.71 
11.16 
7.73 
6.61 
Ρ 
0.0001 
0.0008 
0.0054 
0.01 
Fraction of concordant pairs of predicted probabilities and responses: 
0.792 
Rank correlation between predicted probability and response: 0.596. 
»Dependent variable: control/PVD 
Independent variables: smoking, VLDL+IDL-chol, LDL-chol, apo A-I, 
VLDL+IDL-apo B, LDL-apo В and ratio apo A-I/total apo B. 
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By stepwise logistic regression analysis of all parameters (Table 5) 
it was found that, in order of significancy, the model with smoking, 
LDL-apo B, apo A-I and VLDL+IDL-chol had the highest discriminatory 
power between PVD patients and controls. According to this model the 
probability of a correct prediction of PVD is about BOS. 
Hyperlipoproteineeia in controls and PVD patients Kith relation to the 
apo E polynorphisa 
Hyperlipoproteinemia was more frequent in PVD patients (47S) than in 
controls (27%) (Table 6). Especially in PVD patients with phenotype 
E3/2 or 4/2 and in those with E4/3 or 4/4 hyperlipoproteinemia was 
much more frequent than in the corresponding control groups. Type H a 
and lib was infrequent in patients and controls with E3/2 or 4/2, but 
was particularly present in the E3/3 and E4/3-i£4/4 groups of both ca-
tegories. Type IV was the common type of hyperlipoproteinemia in asso-
ciation with the E3/2 or E4/2 phenotype in both groups. In the 
E3/2+E4/2 PVD patients type IV occurred more frequent in comparison 
with PVD patients with other phenotypes and E3/2+4/2 controls. These 
differences, however, were not significant. 
DISCUSSION 
This study was performed to find out whether the apo E polymorphism, 
lipoproteins and apolipoproteins contribute to the risk of (premature) 
peripheral vascular disease. Therefore, PVD patients were compared 
with controls without signs of vascular disease, who were matched for 
sex, age and relative weight, but not for smoking (Table 1). Patients 
with diabetes or hypertension were not admitted, to exclude these 
known aetiologic causes of vascular insufficiency. 
On the ground of the apo E phenotype distribution in the PVD and con-
trol groups (Table 2) in our study no significant role of the apo E 
polymorphism for the risk of PVD could be established in this study. 
In the PVD group no E2/2 subject, whether normo- or hyperlipidemic, 
was found. Type III hyperlipoproteinemia, which has been associated 
with the E2/2 phenotype, is known to predispose for PVD (B). The rare 
E4/2 phenotype was surprisingly as frequent as the E3/2 phenotype; 
however the frequency of E-2 heterozygotes was similar in the PVD 
patients and controls. 
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Table 6 Occurrence of hyperlipoproteinemia in peripheral vascular disease (PVD) in relation to the apo E phenotype. 
Controls (n=151) 
E3/2+£4/2 E3/3 E4/3+£4/4 
HLP* η (.%) η (Й) η (S) 
IIA 1 (4) 4 (6) 6 (11) 
IIB - 3 (4) -
IV 4 (15) 12 (17) 8 (15) 
V - - 1 (2) 
normal 21 (81) 53 (73) 38 (72) 
η 26 (100) 72 (100) 53 (100) 
TOTAL 
η (S) 
11 (7) 
3 (2) 
24 (16) 
1 (1) 
112 (74) 
151 (100) 
PVD (n=76) 
E3/2-f£4/2 E3/3 E4/3-^4/4 
η (Si) η (%) η (SO 
2 (4) 5 (21) 
1 (10) 4 (10) 2 (8) 
4 (40) 11 (26) 7 (29) 
5 (50) 25 (60) 10 (42) 
10 (100) 42 (100) 24 (100) 
TOTAL 
η (SO 
7 (9) 
7 (9) 
22 (29) 
40 (53) 
76 (100) 
* Hyperlipoproteinemia. 
Classification according to WHO criteria (Bull. WHO 1970; 43: 891-915). 
So far, no other studies on the apo E polymorphism in PVD patients are 
available for comparison. Indeed, similar studies were done in 
patients with coronary artery disease (14-16), however, they came to 
different conclusions. The largest study was that of Menzel et al. 
(14), who demonstrated a protective effect for the e2 allele against 
coronary atherosclerosis, comparing patients with angiographically 
assessed coronary artery disease (n=469) with those without angiogra­
phic abnormalities (n=439). No such effect was found, however, when 
patients with coronary artery disease were compared with 1000 factory 
employees, which was confirmed by others (15,16,22). 
In the PVD group higher levels for serum lipids, VLDL lipids and LDL-
cholesterol were found compared to controls (Table 3), whereas lower 
HDL-cholesterol levels. These findings agreed roughly with previous 
reports, although divergent inclusion criteria for patient selection 
were used (23-2Θ). With hepann-sepharose chromatography it was demon­
strated that the remnant concentration (heparin bound cholesterol) was 
increased in PVD subjects. Topping et al. (29) speculated that smoking 
might cause a delay in the removal of remnants, leading to a predispo­
sition for PVD as in Type III HLP. To test this hypothesis, we made 
a comparison in both the control and PVD groups between those sub­
jects, who smoked more than 20 cigarettes a day and those who did 
smoke less than 20 or not at all. No significant difference in the 
amount of remnants was observed between the groups with distinct 
smoking habits in the PVD as well as the control group (results not 
shown), so that there is no evidence for this hypothesis. 
The concentrations of the apolipoproteins in PVD patients compared to 
controls, i.e. a lower apo A-I and A-II and higher levels of total apo 
B, VLDL+IDL and LDL-apo B, are generally in agreement with other stu­
dies (23,25-28). Despite a rise in the level of the VLDL+IDL lipids 
and the remnant concentration there was no increase in the level of 
total apo E. An increase in VLDL+IDL apo E, however, might be accom­
panied in PVD patients by a decreased apo E in HDL, resulting in the 
same total apo E concentration as controls. 
By logistic regression analysis (Table 5) smoking, LDL-apo B, apo A-I 
and VLDL+IDL-cholesterol in this order appeared to be the most signi­
ficant determinants for PVD. These findings are consistent with the 
current opinion that smoking is the most important risk factor in PVD 
(30) and that apoproteins or apoprotein ratios, such as apo A-I/apo В 
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may be better indicators in predicting atherosclerotic risk than serum 
lipids and lipoproteins (27,31). Furthermore it appeared that VLDL+ 
IDL-cholesterol seemed to be a stronger пак factor in this PVD popu­
lation than LDL-cholesterol. This finding corresponds to the high in­
cidence of peripheral atherosclerosis in Type III hyperlipoproteinemic 
patients, who also have elevated concentrations of VLDL+IDL cholester­
ol, due to accumulation of remnants (8). Franceschim et al. (26) also 
established elevated VLDL-cholesterol levels in their PVD patients and 
moreover an ennchement with apo В in the VLDL fraction. However, 
their suggestion that VLDL-apo В might have a discriminatory power in 
PVD was not confirmed in our larger patient group. 
The influence of the apo E polymorphism on the various biochemical 
parameters (Table 4) and the occurrence of hyperlipoproteinemia (Table 
6) was studied by making a subdivision of both the control and PVD 
group into three apo E phenotype classes. A remarkable finding was 
that in the E3/2+4/2 PVD patients the mean VLDL+IDL lipid levels were 
twice as high as in the corresponding control group, whereas LDL-chol­
esterol was quite similar. The combination with a higher concentration 
of heparin bound cholesterol is indicative for a partial remnant remo­
val defect in these PVD patients. 
The occurrence of hyperlipoproteinemia in our PVD patients agreed very 
well with previous reports (23,32). In 50л of the E-2 heterozygous PVD 
subjects a hypertriglyceridemia (1 Type lib and 4 Type IV) was present 
in contrast to only 15SS in their controls (Table 6). In fact these 
findings support the assumption made by Utermann et al. (33) that 
there may be an increased risk for peripheral vascular disease when 
apo E phenotype E3/2 or E4/2 is associated with hypertriglyceridemia, 
because of an elevated concentration of atherogenic remnants. 
Hypercholesterolemia Type H a and IIb was more frequent in patients 
with the E4/3 or 4/4 phenotype, compared with the other patients and 
their corresponding controls. So, patients with the E4/3 or E4/4 apo E 
phenotype might have a predisposition for PVD predominantly by ele­
vated LDL-cholesterol levels (Table 4). Although the apo E phenotype 
distribution is not an independent risk factor in PVD, these data 
suggest, that in combination with certain (genetic) forms of hyper-
lipidemia the apo E polymorphism may modify the atherosclerotic risk 
by influencing VLDL+IDL- and LDL-cholesterol levels. This assumption 
is supported by epidemiologic studies (11-13,33). Definite evidence 
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for this hypothesis, however, deserves studies in larger patient 
populations. 
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SUMMARY 
Apo E phenotypes were determined in patients with hyperlipoprotein-
aemia and compared with normolipidaemic controls. Patients were either 
classified as Type IIA, IIB, III, IV and V, or according to increments 
of serum lipid levels in: hypertnglycendaemia, mixed hyperlipidaemia 
and hypercholesterolaemia. Apo E phenotype frequencies were similar in 
Type IIA and IIB patients and in controls. All Type III subjects had 
phenotype E2/2. The apo E phenotype distribution in Type IV and Type V 
differed significantly from controls. In Type IV the incidence of phe­
notypes E4/3 and E3/2 was increased, whereas in Type V higher frequen­
cies for E3/2 and E4/2 at the expense of phenotype E3/3 were observ­
ed. In hypertnglycendaemia a significantly higher incidence of phe­
notype E4/3 was found. Mixed hyperlipidaemia was frequently associated 
with phenotypes E3/2 and E2/2. Patients with hypercholesterolaemia had 
the same apo E phenotype frequencies as controls. E-2 heterozygous 
phenotypes in comparison to phenotypes without the e2 allele were in 
controls associated with lower LDL-cholesterol levels, but not in 
patients with hyperlipoproteinaemia. Controls and Type II patients 
with apo E phenotype E4/4 tended to have higher serum and LDL-chol­
esterol levels. In E-2 heterozygous Type IV and Type V patients the 
ratio VLDL-cholesterol/serum triglycerides was increased compared to 
those without the e2 allele, suggesting an increase in remnants. In 
type IV patients a ratio above 0.5 was in 49л of cases associated with 
the presence of the ε2 allele in contrast to 19л in those with a ratio 
below 0.5 (p=0.0005). 
It is concluded that the e.2 allele is not only involved in the devel­
opment of Type III, but probably is also associated with Type IV and 
Type V hyperlipoproteinaemia and mixed hyperlipidaemia. Because of in­
creased amount of remnants, E-2 heterozygous Type IV and V patients 
may have an increased risk for atherosclerosis. No specific role of 
the ε* allele was found in hyperlipoproteinaemia although a tendency 
to increase serum cholesterol levels was observed. 
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INTRODUCTION 
Apolipoprotein (apo) E is a polymorphic protein (1), which is found on 
the surface of chylomicrons and very low density lipoproteins (VLDL) 
(2). Three independent alleles, which have been localized on chromo­
some 19, specify the three most common i so forms E-2, E-3 and E-4 
(1,3). E-2 and E-4 each differ from the parent isoform E-3 by single 
amino acid interchanges (Агд^в * Cys and Суздг + Arg, respective­
ly). The resulting charge differences make them easily to.distinguish 
by isoelectric focusing (4). With this method six apo E phenotypes can 
be discriminated in humans (1,3). 
Apo E plays a key role in the recognition and uptake of remnants of 
triglyceride-rich lipoproteins by hepatic lipoprotein receptors 
(5-6). The apo E isoforms differ, however, in their ability to inter­
act with these receptors. Apo E-2 was found to have a strongly reduced 
capacity for binding with the apo B,E receptors on fibroblasts (7,8). 
Homozygosity for the apo E-2 isoform underlies the development of type 
III hyperlipoproteinaemia together with factors, which increase the 
VLDL production (3,9,10). Patients with this inherited lipoprotein 
disorder have increased amounts of remnants, causing premature athero­
sclerotic disease (11). 
Studies in large populations (12-1B) have pointed out reciprocal ef­
fects of the apo E-2 and E-4 alleles on plasma lipid levels. In hyper-
lipidaemic subjects (19,20) the presence of the apo E-2 allele was 
found to predispose for hypertriglyceridaemia and mixed hyperlipid-
aemia. Thus far the precise role of the apo E-4 allele in provoking 
hyperlipidaemia is not fully clear. In two studies (20,21) a signifi­
cant association between the apo E-4 allele and hypercholesterolaemia 
was demonstrated, whereas in two other reports this association was 
either weak (19) or not present (22). On the other hand, an increased 
prevalence of the apo E-4 allele was also described in type V hyper­
lipoproteinaemia (23). However, this was not confirmed by our group 
(24). Nevertheless, these studies all have indicated that the apo E-2 
as well as the E-4 allele can affect lipoprotein metabolism and the 
occurrence of hyperlipidaemia. 
The present study was undertaken first to look for a possible rela­
tionship between the apo E polymorphism and the occurrence of hyper­
lipidaemia and second to find out whether apo E phenotypes can affect 
serum lipid and lipoprotein levels in Type IIA, IIB, IV and Type V 
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hyperlipoproteinaemia. Especially our study was directed on the compa-
rison between heterozygous E-2 patients and those with the other apo E 
(non E-2) phenotypes. In some E-2 heterozygous subjects increased 
amounts of remnants could be demonstrated like in E-2 homozygotes 
(12), suggesting a partial removal defect of remnants. So the presence 
of one apo E-2 allele in combination with hyperlipoproteinaemia, for 
instance Type IV, could raise the atherosclerotic risk in a consider-
able number of these patients by increased amounts of remnants. 
MATERIALS AND METHODS 
Fasting blood samples were obtained from patients (n=501), who visited 
the lipid outpatient clinic of our department. The patients were clas-
sified according to Fredrickson using WHO criteria (25) in Type IIA, 
IIB, III, IV and V hyperlipoproteinaemia (HLP). Type III was diagnosed 
when the ratios VLDL-cholesterol/serum triglycerides and VLDL-choles-
terol/VLDL-triglycerides (expressed in mmol.l-^) were above 0.69 and 
0.92, respectively, when the VLDL showed beta-mobility on agarose 
electrophoresis and when apo E-3 and E-4 bands were absent on isoelec-
tric focusing (26). To compare our results with those of other studies 
(19,20), the patients were also divided according to their serum lipid 
levels in hypertriglyceridaemia (triglycerides above 2.20 mniol.l~1), 
hypercholesterolaemia (cholesterol above 7.2 mmol.l-'') and mixed 
hyperlipidaemia (elevation of both serum cholesterol and triglyce-
rides). Causes of secondary hyperlipidaemia other than obesity, diabe-
tes mellitus and use of alcohol in Type IV and Type V patients were 
excluded. Pretreatment samples of patients were preferably studied, 
however, in all types some patients were on medications and/or dietary 
restrictions. All patients were probands; relatives of hyperlipidaemic 
subjects were excluded. As a reference group we investigated 247 nor-
molipidaemic control subjects, who were mainly hospital workers and 
medical students. Normolipidaemia was defined as serum cholesterol and 
triglycerides below 7.20 and 2.20 mmol.l"^, respectively. 
The methods for determination of serum cholesterol and triglycerides 
and for lipoprotein separation by ultracentrifugation and precipita-
tion have been published elsewhere (27). Apo E phenotypes were deter-
mined by means of isoelectric focusing of VLDL apoproteins, followed 
by densitometric scanning (28). Chi-square statistics (Contingency 
procedure) were used to compare apo E phenotype distributions in the 
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distinct groups. Biochemical parameters in the apo E phenotype groups 
were compared by Student's t-test. P-values less than 5% were consi­
dered to be significant. 
RESULTS 
Apo E phenotype frequencies, serua lipid and VLDL and LDL-cholesterol 
levels in nonnolipidaemic controls 
In the controls phenotypes ЕЭ/3, E4/3 and E3/2 were most commonly 
found in this order (Table 1). Subjects with the E3/2 and E2/2 pheno­
type had lower serum and LDL cholesterol levels (p=0.01) compared to 
the E3/3 phenotype. Higher levels, however, were found in E4/4, E4/3 
and E4/2 subjects. Serum triglyceride levels were similar, except in 
the E4/2 and E2/2 subjects, who showed increased levels. In the E2/2 
subjects the ratio VLDL-cholesterol/serum triglycerides was nearly 
twice as high as in the other phenotypes. In E-2 heterozygous subjects 
this ratio was the same as in subjects with the E3/3, E4/3 and E4/4 
phenotypes. 
Apo E phenotype (S) and allele frequencies in controls and various 
types of hyperlipoproteinaeaia 
The apo E phenotype distribution in different types of hyperlipopro-
teinaemia (HLP) is shown in Table 2. In Type IIA and Type IIB a simi­
lar pattern was observed as in controls. No significant difference in 
apo E phenotype distribution was found between familial and polygenic 
Type H A (results not shown). One of the Type IIA patients (age 59 
yrs.; serum cholesterol and triglycerides 15.03 and 2.00 mmol.l-^, 
respectively, and LDL-cholesterol 11.53 mmol.l"'') had the E2/2 phe­
notype. The phenotype distribution of Type IV and V differed signifi­
cantly from controls. In both type IV and V the incidence of E3/3 was 
decreased compared to controls. In Type IV a higher frequency of E3/2 
and E4/3 was observed, whereas in Type V apo E phenotype E3/2 and E4/2 
were more common than in controls. One male hypertnglyceridaemic 
patient with the apo E phenotype E2/2 (age 50 yrs.; serum cholesterol 
and triglycerides 5.96 and 2.91 mmol.1-1, respectively) was classi­
fied as Type IV, because the ratio VLDL cholesterol/serum triglyce­
rides did not met the criteria for type III HLP (see methods). Accord­
ing to our diagnostic criteria (see materials and methods) all type 
III patients (n=42; Table 2) had the E2/2 phenotype. Considering these 
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Table 1 Арю E phenotype and mean levels of serum cholesterol, triglycerides, VLDL-cholesterol and LDL-cholesterol 
(mmol.1-1 + SD) in normolipidaemic controls (n=247) 
phenotype η Cholesterol Triglycerides VLDL-chol LDL-chol VLDL-chol/serum TG 
E3/3 
E4/3 
E 3/2 
E4/2 
E4/4 
E2/2 
»prO.01 
p=0.004 
vs 
νε 
142 
48 
40 
5 
10 
2 
E 3/3 
ì E4/3 
57.5 
19.4 
16.2 
2.0 
4.0 
0.8 
5.07+0.98 
5.15+0.92 
4.80+0.88 
5.79+0.79 
5.45+1.13 
4.28+0.93 
1.14+0.38 
1.26+0.48 
1.14JD.39 
1.49+0.65 
1.02+0.25 
1.53+0.24 
0.36+0.19 
0.38+0.20 
0.41+0.24 
0.53+0.23 
0.35+0.19 
0.97+0.08 
3.40+0.92 
3.52+0.84 
3.02+0.78* 
3.99+0.56 
3.72+1.02 
2.17+0.95 
0.30+0.10 
0.30+0.10 
0.33+0.13 
0.32+0.12 
0.32+0.12 
0.65+0.16 
phenotype frequencies as a direct reflection of the inherited apo E 
alleles, there was an increase in the calculated ε2 allele frequency 
from Type IIA up to Type V HLP, whereas there was a decrease in the 
occurrence of the e4 allele in the opposite direction (Type III ex­
cluded) . 
Table 2 Apo E phenotype distribution (%) and allele frequencies in 
normolipidaemic controls and various types of hyperlipopro-
teinaemia. 
Phenotype 
E3/3 
E4/3 
E3/2 
E4/2 
E4M 
E2/2 
C o n t r o l s 
57.5 
19.4 
16.2 
2.0 
4.0 
0.8 
(n=247) 
I IA 
53.6 
28.2 
10.0 
1.8 
5.5 
1.2 
(n=110) 
I I B 
49.5 
26.4 
15.4 
6.6 
2.2 
-
(n=91) 
I I I 
100 
(n=42) 
IV* 
43.3 
28.1 
21.9 
3.8 
2.4 
0.5 
(n=210) 
V** 
35.5 
21.7 
34.5 
8.3 
2.1 
-
(n=4B) 
A l l e l e 
e2 
ε3 
ε4 
0.099 
0.753 
0.148 
0.068 
0.727 
0.205 
0.110 
0.703 
0.187 
1.000 
0 
0 
0.133 
0.683 
0.183 
0.208 
0.625 
0.167 
* X2df5 = 12.49; ρ = 0.03 Type IV vs. controls 
**X2df5 = 15.94; ρ = 0.007 Type V vs. controls 
Apo E phenotype and allele frequencies in hypertriglyceridaenia (HT), 
•ixed hyperlipidaemia (HT+HC) and hypercholesterolaeaia (HC) 
The apo E phenotype frequencies were also studied after dividing the 
patients in a hypertriglycendaeroic, hypercholesterolaemic and mixed 
hyperlipidaemic group (Table 3). The apo E phenotype distribution 
differed significantly between controls and both patients with hyper-
triglycendaemia and mixed hyperlipidaemia, but not between controls 
and patients with hypercholesterolaemia. 
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Table 3 Apo E phenotype distribution (Sí) and allele frequencies in 
normolipidaemic controls, hypertriglyceridaemia (HT), mixed 
hyperlipidaemia (HT+HC) and hypercholesterolaemis (HC) 
Phenotype 
E3/3 
E4/3 
E3/2 
E 4/2 
E 4 A 
E 2/2 
Con t ro l s (%) 
57.5 
19.ft 
16.2 
2.0 
4.0 
0.B 
(n=2ft7) 
HT (S ) * 
4ft.1 
30.1 
17.5 
2.8 
2.1 
3.5 
(n=1ft3) 
HT+MC ( » ) * * 
36.7 
21.9 
20.3 
3.9 
2.3 
1ft.θ 
(n=256) 
HC (S) 
56.1 
25.5 
10.2 
2.0 
5.1 
1.0 
(η=9θ) 
A l l e l e 
e2 
e3 
eft 
0.096 
0.7ftft 
0.160 
0.136 
0.678 
0.185 
0.270 
0.578 
0.152 
0.071 
0.7ft0 
0.189 
* X^dfS = 12.50; p=0.03 vs controls 
**X*df5 = ft6.86; p<0.0001 vs controls 
X^dfS = 15.43; p=0.008 vs HT 
X^dfS = 25.64; p=0.0001 vs HC 
In patients with hypertriglyceridaemia the Eft/3 phenotype was more 
frequently observed at the expense of the E3/3 phenotype. Patienta 
with combined hyperlipidaemia differed from controls primarily because 
of the higher frequency of the E2/2 (Type III!) and E3/2 phenotypes. 
Consequently, the e2 allele was relatively more frequently found in 
the patients with combined hyperlipidaemia and also to a minor extent 
in the hypertriglyceridaemic patients. The occurrence of the eft allele 
seemed to be the same in the hypertriglyceridaemic and hyperchol-
esterolaemic patients. 
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Table 4 Comparison of mean serum lipid and lipoprotein levels (mmol.1-1 + SD) of patients with hyperlipoproteinaemia 
with reference to the presence (E-2 heterozygotes) or absence (non E-2) of the E-2 isoform*. 
category cholesterol triglycerides VLDL-chol LDL-chol VLDL-chol/TG 
Type IIA 
non E-2 
E-2 heterozygotes 
Type II-B 
non E-2 
E-2 heterozygotes 
Type III 
E2/2 
Type IV 
non E-2 
E-2 heterozygotes 
Type V 
non E-2 
E-2 heterozygotes 
97 
13 
71 
20 
42 
156 
54 
2B 
20 
9.00+1.52 
9.28+1.70 
8.66+0.90 
8.80+1.01 
11.18+4.34 
6.76+1.18 
6.97+1.24 
10.82+6.17 
14.64+5.99** 
1.65+0.56 
1.80+0.76 
3.57+1.09 
2.98+0.99** 
7.38+5.51 
4.51+1.72 
4.37+1.63 
27.02+26.58 
29.71+22.82 
0.66+0.40 
0.87+0.47 
1.57+0.59 
1.47+0.73 
6.69+4.32 
1.92+0.88 
2.18+0.92 
7.55+5.74 
11.19+5.65** 
7.14+1.45 
7.16+1.44 
6.09+0.71 
6.29+0.82 
3.44+0.89 
3.95+0.87 
3.87+0.86 
2.64+1.27 
2.86+1.53 
0.39+0.16 
0.49+0.17 
0.44+0.09 
0.48+0.12 
0.97+0.28 
0.43+0.12 
0.50+0.13 
0.33+0.11 
0.44+0.16** 
* Results of E-2 homozygotes in Type III included for reason of comparison 
**p<0.05, p<0.001 vs non E-2 
Comparison of seru· lipid and lipoprotein concentrations of patients 
Mith hyperlipoproteinaefliia in relation to the presence or absence of 
the apo E-2 allele 
To study a possible effect of the heterozygous E-2 phenotype on serum 
lipid and lipoprotein levels in the various types of hyperlipoprotein-
aemia (Table 4) , the patients of each group were divided in two apo E 
phenotype groups according to the absence or presence of the allele 
for apo E-2: the non E-2 group (E3/3, E4/3 and E4/4) and the hetero­
zygous E-2 group (E3/2 and E4/2). In the non E-2 group of each type of 
hyperlipoproteinaemia no significant differences in the shown lipopro­
tein parameters were observed between the apo E phenotypes E3/3, E4/3 
and E4/4. For reasons of comparison also the data of patients with 
type III HLP are shown. In patients with Type IIA no differences were 
found between both phenotype groups. In Type IIB serum triglycerides 
were significantly lower in the heterozygous E-2 group. In comparison 
with non E-2 subjects the ratio VLDL-cholesterol/serum triglycerides 
was significantly higher in E-2 heterozygous Type IV and V hyperlipo-
proteinaemic groups; in the other groups the differences were insigni­
ficant. In Type V HLP serum cholesterol and VLDL-cholesterol were sig­
nificantly higher in the E-2 heterozygous individuals compared to non 
E-2 subjects with Type V. 
Table 5 Relation between VLDL-chol/serum triglycerides 
ratio (R) and apo E phenotype in subjects with 
type IV hyperlipoproteinaemia. 
Phenotype 
E 3/3 
E4/3 
E 3/2 
E4/2 
E4/4 
E2/2 
total 
η 
72 
53 
25 
5 
4 
0 
159 
R<0. ,5 
% 
45.3 
33.3 
15.7 
3.1 
2.5 
-
η 
19 
6 
21 
3 
1 
1 
51 
R>0, .5* 
% 
37.5 
11.8 
41.2 
5.9 
2.Q 
2.0 
*X2df5 = 22.32 ρ = 0.0005 
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Dividing the Type IV patients into two categories, according to the 
level of the ratio VLDL-cholesterol/serum triglycerides above or below 
0.5 (Table 5), a significant difference in apo E phenotype distribu-
tion between both categories was found. Forty-seven % of the Type IV 
patients with relatively high concentrations of remnants (ratio >0.5) 
appeared to be heterozygous for apo E-2 in contrast to 222» of those 
with lower levels (ratio <0.5). 
DISCUSSION 
The present study was primarily focused on the hyperlipidaemic popula-
tion in search of a possible association of the apo E polymorphism 
with distinct forms of hyperlipoproteinaemia and with serum lipopro-
teins. For reason of comparison a normolipidaemic control group was 
included. 
The observed apo E phenotype frequencies in Dutch normolipidaemic con-
trols (Table 1) correspond with those found in Germany (1,13), New 
Zealand (14) and North America (3,15,18), but differ from Finnish (16) 
and Japanese populations (17)· The phenotype distributions in patients 
with Type IIA and Type IIB (Table 2) and in those classified as hyper-
cholesterolaemia (Table 3) differed not significantly from the control 
data. There was, however, a trend to a higher prevalence of the eft 
allele in these subjects (Table 2 and 3), so that the conclusions of 
previous reports (21,22) cannot be contradicted by our results. In 
consequence of our diagnostic criteria, all Type III patients possess-
ed the E2/2 phenotype. 
Patients, either classified as Type IV or as hypertriglyceridaemic had 
a higher occurrence of phenotypes E4/3 and to a lesser extent also of 
E3/3 compared to controls, which was also found by Eto et al. (29). 
Other groups found only a higher frequency of the E3/2 phenotype in 
Type IV (22) or in hypertriglyceridaemic patients (19,20). So these 
results indicate a possible contribution of the eh allele to the de-
velopment of distinct forms of hyperlipoproteinaemia and not merely to 
hypercholesterolaemia as was found by others (20,21). 
Thirty-four % of our Type V patients were heterozygous for apo E-2. As 
we reported previously (24) these results disagree with those of 
Chisel li et al. (23). In Type V subjects with similar serum lipid 
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values they found an increased prevalence of apo E-4. Their finding, 
that apo E-4 is faster metabolized than apo E-3 (30) and the normal 
receptor binding properties of both apo E-3 and E-4 (Θ) makes an asso­
ciation of apo E-4 with Type V HLP difficult to explain. They specu­
lated (30) that apo E may modulate the hydrolysis of large triglyce-
ride-rich lipoproteins, but thus far only remnant particles (ß-VLDL), 
containing the abnormal E-2 isoform, were found to be a bad substrate 
for in vitro lipolysis (31,32). 
A relatively high incidence of the ε2 allele was also demonstrated in 
patients with mixed hyperlipidaemia. This is largely explained by the 
presence of nearly all Type III patients in this group, but also can 
be ascribed to a majority of patients with severe hypertriglycerid-
aemia (Type V) being classified in this group. 
Thus far, the relationship between apo E phenotypes and lipoprotein 
levels in hyperlipidemics was not studied. Because hyperlipidaemic E-2 
heterozygotes may have a partial removal defect of VLDL-remnants (12), 
levels of serum lipids and lipoproteins are mentioned for each type of 
HLP in relation with apo E phenotype groups (Table 3). For this pur­
pose two apo E phenotype groups were considered according to the pre­
sence (E3/2 + E4/2) or absence (E3/3 + E4/3 + E4/4) of the E-2 iso­
form. One point of interest in this part of the study was the finding 
that the presence of the E-2 isoform exerts only in controls a signi­
ficant LDL-chol lowering effect in comparison to non E-2 subjects and 
not in any of the HLP groups. In contrast to the control group, the 
ratio VLDL-cholesterol/serum triglycerides was elevated in E-2 hetero­
zygous Type IV and Type V patients. We demonstrated previously a nor­
mal disappearance of chylomicron remnants after a fat load in normo-
lipidemic E-2 heterozygous subjects (33). So, these results indicate 
that in E-2 heterozygous subjects a partial removal defect only be­
comes apparent in case of hypertriglyceridaemia (Type IV and Type V 
HLP), but not under normolipidaemic conditions. 
Studying in Type IV patients the influence of the apo E polymorphism 
on the amount of remnants, estimated by the ratio VLDL-cholesterol/ 
serum triglycerides, indeed twice as much of the Type IV patients with 
a ratio above 0.5 possessed the ε2 allele than those with a ratio be­
low 0.5. So, a number of E-2 heterozygous subjects with Type IV HLP 
may have an increased risk for atherosclerotic disease because of in­
creased amount of remnants, in spite of low LDL-cholesterol levels. 
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Heterozygosity for apo E-2 in normolipidaemic subjects does not appear 
to be a risk factor and may even protect against atherosclerosis be­
cause of normal remnant and low LDL levels (13). 
It has been supposed by others (30,34) that in homozygous E-2 subjects 
a defect in the catabolism of triglyceride-rich lipoproteins may lead 
to an upregulation of the B,E receptors and consequently lower LDL-
cholesterol levels. As our E-2 heterozygous controls had lower LDL-
cholesterol levels than non E-2 controls one would expect the same in 
E-2 heterozygous hyperlipidaemics. This was, however, not the case, 
neither in Type IV nor in Type V HLP. 
E-4 homozygous controls (Table 1) and E-4 homozygous Type II, but not 
Type IV patients tended to have higher serum and LDL-cholesterol 
levels (data not shown), but their numbers were too small to reach 
statistical significance. These findings are in agreement with other 
studies (15-18). 
In conclusion, the apo E alleles E2 and EA contribute to the variation 
of serum lipids and lipoproteins and are associated with hyperlipid­
aemia. An association was found between heterozygosity for the e2 
allele and Type IV and V HLP and mixed hyperlipidaemia. Because of a 
partial removal defect of remnants, subjects with these forms of HLP 
may be at risk for atherosclerotic disease, like Type III patients. 
Therefore, determination of the apo E phenotype may contribute as a 
diagnostic tool in the search for patients at risk. The role of the eA 
allele was in this study not related to hypercholesterolaemia or Type 
V HLP and seems to be more complex. 
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Catabolism of chylomicron remnants in 
normolipidemic subjects in relation to 
the apoprotein E phenotype1 
Bernard J. Brenninkmeijer, Paul M. J. Stuyt, Pierre N. M. Demacker, Anton F. H. 
Stalenhoef, and Albert van 't Laar 
Department of Medicine, Division of General Internal Medicine, University of Nijmegen, Nijmegen, 
The Netherlands 
Abstract The role of the vanous apolipoprotcin E isoprotcins 
in the removal of chylomicrons and their remnants from plasma 
was studied in 16 normolipidemic subjects with various apoE 
phenotypes 5 homozygous for apoE-2, б heterozygous for apoF 
2 (phenotype E3/2), and 5 without apoE-2 (phenotypes ЬЗ/3, 
E4/4, and E4/3) The subjects were given an oral fat load as 
cream (50 g/m2) Retmyl palmitate was added as a marker for 
chylomicrons and their remnants Blood was sampled at regular 
time intervals for 8 hr Remnant particles were isolated from the 
d < 1 019 g/ml fraction by heparin Sepharose chromatography 
(hepann bound fraction) after removing the large chylomicrons 
by flotation at 7,8 χ 105£ mm All groups showed a rise in tngly 
cendes in serum and in the chylomicron fraction between 3 and 
6 hr to about twice the basal value, followed by a decrease to 
nearly fasting values In the homozygous E 2 subjects, fasting 
lipids in the remnant fraction were increased In all three groups 
the fat load did not induce a significant rise in the lipids of the 
remnant fraction The homozygous E-2 group showed a strong 
continuing rise in the retinyl palmitate concentration in the chy 
lomicron and remnant fractions up to 8 hr, whereas in the other 
groups its maximum was already reached at 5 hr at a much 
lower level At 8 hr similar retinyl palmitate concentrations were 
found in both fractions in the heterozygous E 2 subjects com­
pared to the non L· 2 subjects DO These results indicate a 
delayed removal of chylomicrons and chylomicron remnants in 
normolipidemic homozygous E-2, but not in heterozygous E-2 
subjects —Brenninkmeijer, B. J., Ρ M J. Stuyt, P. Ν M 
Demacker, A. F. H Stalenhoef, and A. van t Laar. Catabo 
hsm of chylomicron remnants in normolipidemic subjects in 
relation to the apoprotein I* phenotype J Lipid Res 1987 28. 
361-370 
Supplementary key wonls apoE polymorphism · retinyl palmitate 
by a seriously delayed uptake of remnants in the liver 
because of a defective recognition of these particles by 
specific lipoprotein receptors (2, 3) Apolipoprotcin 
(apo)E, an important surface component of remnants and 
critical to this process of recognition, is functionally ab­
normal m type III hyperlipoproteinemia (2-6) In 
general, three major apoE isoprotems, apoE-2, E-3, and 
E-4 are known (7) T h e synthesis of these isoprotems is 
genetically controlled by three co-dominant alleles (e2, e3, 
and í4) on one polymorphic genetic locus (8) Homozygo-
sity for apoE-3 (phenotype E3/3) occurs most frequently 
(about 60% of the general population), whereas homozy-
gosity for the E-2 isoprotein (phenotype E 2/2) is relative-
ly rare (about 1% of the population), heterozygosity for 
apoE-2 (phenotypes E3/2 and E4/2) occurs in about 18% 
(8-11) These apoE isoprotems differ from each other by 
single amino acid substitutions in the primary structure 
of the molecule (12) In general, f 2 and e4 are associated 
with hypertnglycendemic and hypercholesterolemic 
states, respectively (13-16) Homozygosity for apoE-2 
(phenotype E2/2) is associated with type III hyperlipopro-
teinemia (8, 9, 17) However, only 1% of all subjects with 
this phenotype develops hyperlipidemia Accompanying 
factors, increasing the V L D L production, are required 
for the development of this condition, such as several 
genetic forms of hyperlipidemia, hypothyroidism, glucose 
intolerance, and obesity (17) Although the great majority 
of subjects with phenotype E2/2 are normolipidemic, at 
least in the fasting state, these subjects also possess 
Type III hyperlipoproteinemia (familial dysbetalipo-
proteinemia) is a genetic disorder of lipoprotein metabo-
lism with a strong predisposition to coronary and 
peripheral artery disease, caused by an accumulation of 
remnants of both chylomicrons and very low density lipo-
proteins (jS-VLDL) (1-3) This disorder is characterized 
Abbreviations apoE, apolipoprotcin E HDL, high density lipopro-
teins, (d > 1 063 g/ml), LDL, low density lipoproteins (1 019 < d < 1 063 
g/ml), RP, retmyl palmitate, VI DI + IDL very low density lipopro 
teins plus intermediate density lipoproteins (d < I 019 g/ml) 
'Part of this work was presented at the 57th Scientific Session of the 
American Heart Association (Circulation 1984 70-II 269) 
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0 V L D L , as is evident from the cholesterol enrichment 
and β mobility on agarose electrophoresis of their V L D L 
fraction (17) In addition, the structural and receptor bin 
ding defects of apoE 2 are identical in normo- and 
hyperhpidcmics (18) E-2 heterozygous subjects also have 
the defective E 2 isoform and some of them may have β 
V L D L as well Rarely, E 2 heterozygosity is associated 
with type III hyperlipoproteinemia (16, 19) 
Thus, in normohpidemics, heterozygosity as well as 
homozygosity for apoE 2 might be associated with a 
defective removal of remnants This may become parti­
cularly apparent in the postprandial state, when the lipo­
protein receptor system is challenged to a greater extent 
Therefore, we administered oral fat loads to healthy 
normolipidemic subjects with different apoE phenotypes 
and studied the metabolic fate of chylomicrons and their 
remnants For this purpose retinyl palmitate (ЯР) was 
added to the fat load as a marker for the chylomicron 
remnants, which were isolated by means of heparin 
Sepharose chromatography of the lipoprotein fraction 
with density less than 1 019 g/ml 
M A T E R I A L S A N D M E T H O D S 
Subjects and study protocol 
Sixteen normolipidemic volunteers participated in the 
study AU were healthy male hospital workers or medical 
students and were selected after apoE phenotype screen­
ing Two of the five E-2 homozygous subjects, however, 
were detected by screening relatives of probands with type 
III hyperlipoproteinemia (18) They were divided into 
three groups, according to their apoE phenotype 1) the 
non-E-2 group, consisting of five subjects without the 
apoE allele (2 (three subjects with apoE phenotype E 3/3, 
one with E4/3, and one with E4/4), 2) the heterozygous 
E-2 group, consisting of six subjects, all with phenotype 
E3/2, and 3) the homozygous E 2 group Some clinical 
characteristics are summarized in Table 1. All subjects 
were on a normal diet and did not take drugs or excessive 
alcohol After informed consent had been obtained from 
each subject, they were studied in the outpatient clinic 
After an overnight fast of 12 hr, the subjects were given 
an oral fat load of 50 g/m1 as cream (per 100 g cream 35 
g of fat, 2 g of protein, and 2 8 g of carbohydrates), con 
taming 150,000 IU of R P Blood samples were taken by 
venipuncture into vacutainer tubes at 0, 2, 3, 4, 5, 6, and 
8 hr after the fat load and were spun within 2 hr to 
separate the serum During this time the subjects did not 
take meals T h e sera were stored in the dark for 16-23 hr 
at 4 0 C under nitrogen before lipoprotein isolation was 
carried out In all samples cholesterol and tryglycendes 
were determined in total serum and lipoprotein fractions, 
R P was measured in chylomicrons and remnants, which 
were isolated by heparm-Sepharose chromatography of 
the fraction with d < 1 019 g/ml 
M E T H O D S 
Chylomicrons were isolated by carefully overlayering 3 
ml of serum at room temperature with 5 ml of saline of 
density 1 006 g/ml The tubes were centnfuged for 30 mm 
1 Clinical characteristics and fasting plasma lipid levels of the non E 2 group (apoE phenotypes 
E 4/4 E 4/3 or E 3/3), the heterozygous E 2 group (apoE phenotype E 3/2) and the 
homozygous E 2 group (apoF phenotype F 2/2) 
Number' 
Ag* (YO 
Height (cm) 
Rel weight (%) ' 
Scmm chol1 
Senim T G ' 
Chyl T G 
VLDL + IDL chol 
VLDL + IDL T G 
, ^ , , η VLDL + IDL chol 
scram TG 
LDL-chol 
HDL-chol 
'All tubjects are males 
Non F 2 
25 
184 
97 
4 54 
1 16 
0 14 
0 49 
0 64 
0 43 
2 β 3 
1 13 
A c u a l body we.ght „ , „ „ „ , 
5 
± 4 
± 4 
± 4 
± 0 62 
± 0 33 
± 0 14 
± 0 12 
± 0 24 
± 0 07 
± 0 64 
± 0 29 
on 1983 Metre 
E 2 Heterozygotes 
mean 
6 
28 ± 
183 ± 
113 ± 
4 39 ± 
1 06 ± 
0 19 ± 
0 54 ± 
0 47 ± 
0 55 ± 
2 53 ± 
1 30 ± 
± SD 
7 
6 
13' 
0 85 
0 47 
0 15 
0 31 
0 26 
0 21 
0 45 
0 38 
>politan height and weight tat 
E 2 Homozygotes 
32 
181 
103 
3 58 
1 34 
0 14 
100 
0 83 
0 75 
1 47 
1 11 
.les) 
5 
± 12 
± 6 
± 9 
± 0 52 
± 0 31 
± 0 07 
± 0 25' 
± 0 14' 
± 0 15' 
± 0 40" 
± 0 09 
ideal body weight 
'Tocal serum and lipoprotein lipid concentrations are in mmol/l chol cholesterol (mg/dl - 38 Bx mmol/1) TG 
tnglyccndes (mg/dl = 88 5x mmol/1) 
'P < 0 05 vs non E 2 
'Ρ < 0 05 vs non E 2 and E 2 heterozygotes 
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at 14,000 rpm (7 8 χ 10' g-min) in the Ι E С B-60 ultra­
centrifuge (Damon Ι E С , Needham Heights, MA) us­
ing the SW 41 swinging bucket rotor at 2 0 o C The 
chylomicrons were recovered by aspirating the first 4 5 ml 
with a Pasteur pipette The infranatant was mixed and 
quantitatively transferred into a different ultracentrifuge 
tube The density was then raised to 1 019 g/ml by addi­
tion of DjO and the tubes were spun overnight for 16 hr 
at 40,000 rpm (168,000 g) in the fixed SW angle rotor no 
468 at 14°C The top layer, containing the VLDL + IDL 
fraction, was isolated and then fractionated by heparin-
Sepharose chromatography according to Shelburne and 
Quarfordt (20) with commercially available columns 
(Lipotype™ Biolab, Amersfoort, the Netherlands) into 
two subfractions one, not binding to heparin-Sepharose 
and eluting with 0 05 M NaCl, and a second fraction, 
binding to heparin-Sepharose and eluting with 1 0 M 
NaCl The cholesterol concentration in the heparin-
Sepharose-bound fraction was taken as an estimate for the 
chylomicron- and VLDL-remnant concentration The 
coefficient of variation for replicate analyses of cholesterol 
in the heparin-Sepharose bound- and unbound fractions 
of a VLDL + IDL pool was 6 0% and 7 1%, respectively 
(n = 10), the recovery of lipoprotein-associated choles­
terol after heparin-Sepharose chromatography ranged 
from 95 to 105% (n = 10) This method of estimating the 
concentration of remnants was validated in a preliminary 
study by analyzing VLDL fractions (d < 1 006 g/ml) from 
fasting serum of normohpidemic subjects and patients 
with type III and type IV hyperlipoproteinemia In all 
subjects the concentration of cholesterol relative to trigly­
cerides was about twice as high in the hepann-Sepharose-
bound fraction as in the unbound fraction (Table 2). 
Furthermore, the apoE/apoC ratio, determined by den-
sitometnc scanning of isoelectric focusing gels (21), was 
also considerably higher in the heparin-Sepharose-bound 
fraction (Table 2) On agarose gel, the electrophoretic 
mobility of the heparin-Sepharose-bound fraction was 
predominantly between the (3 and pre-ß position, whereas 
the unbound fraction migrated mainly to the pre-j3 
position 
The high density lipoprotein (HDL) fraction was 
isolated in whole serum using the polyethylene glycol-
6000 precipitation method (22) Cholesterol and trigly-
cerides were determined by enzymatic methods 
(CHOD-PAP reagent no 237574, Boehnnger, Mann-
heim-GFR, and sera-PAK triglycerides, Milan, Italy) us-
ing a centrifugal analyzer (Multistat III) LDL-
cholesterol was calculated as the difference between the 
cholesterol content in the d 1 019 g/ml infranatant and 
HDL-cholesterol 
One-dimensional isoelectric focusing of VLDL apopro-
teins and determination of apoE phenotypes was carried 
out as previously described (21) 
Retinyl palmitate assay 
RP was determined in extracts of chylomicrons as well 
as of the V L D L + IDL ( d < 1 0 1 9 g/ml) subfractions, 
separated by heparin-Sepharose chromatography, by 
means of straight phase high-pressure liquid chromato-
graphy (Si-60, Vanan 8500) For quantitation, 20 μΐ of 
syn-all-'rau retinal oxime (3 06 nmol) was added as an in­
ternal standard to 1 ml of each lipoprotein fraction (23) 
Extraction was performed twice with 4 ml of ace-
tone-diethylether 11 (v/v) The recovery of RP after ex­
traction was 85-95% (n - 10) The extracts were 
combined, dried under nitrogen, and redissolved in 15 μ\ 
of dioxane This solution was diluted with 100 μ\ of hex-
ane, and 40 μΐ of this mixture was applied to the Si-60 col­
umn and eluted isocratically Eluting peaks were detected 
at 328 nm (Schoeffel SF 770) and peak areas were deter­
mined with an HP 3353 data analysis system and con­
verted by means of an internal standard program into 
absolute amounts 
The hexane-dioxane system that was used does not 
separate the various long-chain retinyl esters Upon anal­
ysis with 0 4 % diethylether as eluent, RP was observed to 
be the predominant component (more than 90%) of the 
total retinyl ester population, in agreement with other 
reports (24, 25) Since the hexane-dioxane system strong­
ly reduces analysis time (8 mm), this system has been ap­
plied routinely and the resulting retinyl ester peak was 
TABLE 2 Composition of two subfractiona of VLDL (d < I 006 g/ml) separated by hepann-Sepharose 
chromatography in senjm of fasting normohpidemic subjects and patients with 
type III and type IV hyperlipoproteinemia 
Heparin Sephirose Fraction! 
Bound ratio chol/TG 
ratio apoE/C 
Unbound ratio chol/TG 
ratio apoE/C 
Normal (n - 4) 
0 59 t 0 28 
0 94 1 0 38 
0 25 ± 0 10 
0 12 ± 0 08 
Type III („ . 3) 
mean ± SD 
1 67 ± 0 24 
0 72 ± 0 46 
0 87 ι 0 06 
0 30 ± 0 03 
Type IV („ - 2) 
0 70 ± 0 08 
1 01 ± 0 21 
0 49 ± 0 03 
0 11 ± 0 04 
Choi, cholesterol, TG, triglyceride 
Brmmnkmnjer et al CatabolUm of chylomicron· in normolipidcmic lubjecta 
Θ2 
considered to represent R P T h e R P concentrations 
measured in the chylomicron fraction and in the 
hepann-Sepharose-bound part of the VI,DL + I D L frac­
tion were taken as estimates of the amount of chylomicron 
particles and remnants of chylomicrons, respectively T h e 
recovery of R P after ultracentrifugation in the chylomi­
crons, hepann-Sepharose-bound and unbound fractions 
was over 8 5 % 
Study of the transfer of retinyl palmitate from chy­
lomicrons to lipoproteins with higher densities in vitro 
RP-containing chylomicrons were harvested by ultra­
centrifugation from 48 ml of plasma from a normohpi-
demic donor 4 hr after a fat load of 275 g of cream and 
150,000 IU of R P Two ml of the chylomicron fraction 
(triglycerides, 3 92 mmol/1) isolated from 4 ml of plasma 
was incubated for 5 hr at 3 7 0 C with 3 ml of plasma from 
two non-E-2, two E-2 heterozygous, and two E-2 homozy­
gous acceptors (24) To correct for slight shifts in the 
hydrated densities of the lipoprotein particles during 
ultracentrifugation, blank experiments were performed 
by incubating the same amount of R P - n c h chylomicrons 
with 4 ml of lipoprotein-deficient plasma ( d > 1 25 mg/dl, 
dialyzed against saline) After incubation, 30 m g of 
sucrose was added to each ultracentrifugation tube in 
order to increase the viscosity of the incubation sample to 
the same serum conditions and to facilitate the layering 
procedure The chylomicrons and V L D L + I D L were 
again isolated as described above The density was then 
raised to 1 063 g/ml to isolate the L D L In these lipopro­
tein fractions and in the L D L infranatant, the R P concen­
trations were subsequently measured The results were 
corrected for the R P content already present in the lipo­
protein fractions by incubating 4 ml of the acceptor 
plasma with 2 ml of saline 
Statistical methods 
Mean lipid values and R P concentrations in the various 
lipoprotein fractions were compared by the unpaired and 
paired Student's / test /"-values less than 5% were con­
sidered to be significant 
RESULTS 
Concentrations of serum lipids and lipoproteins before 
and after the fat load 
The non-E-2 and heterozygous E-2 groups had similar 
mean basal levels of serum lipids and lipoproteins (Table 
I) T h e homozygous E-2 group, however, had significantly 
lower mean total serum and LDL-cholesterol concentra­
tions and significantly higher V L D L + I D L cholesterol 
and triglyceride concentrations than the other groups, 
also, the ratio V L D L + IDL-cholesterol/serum trigly­
cerides was increased in this group 
After the fat load was administered there was in all 
groups a rise in the mean serum triglyceride concentra­
tions to about twice the basal value between 3 and 6 hr, 
followed by a decrease to nearly fasting values at 8 hr 
(Fig. 1). The serum triglyceride response was comparable 
in the three groups and proportional to the fasting trigly­
ceride levels T h e changes in the triglyceride concentra­
tion of the chylomicron fraction were similar to those in 
whole serum and no changes were observed in the concen­
tration of chylomicron cholesterol after the fat load In the 
homozygous E-2 group, mean V L D L + I D L cholesterol 
concentrations were at all time points significantly higher 
than in both other normohpidemic groups (Fig. 2). Eight 
hours after the fat load, the E-2 homozygous group had 
a significantly higher V L D L + IDL-tnglycende concen­
tration also 
The cholesterol concentration in the hepann-Sepharose-
bound fraction was twice as high in the homozygous E 2 
group as in both other groups (Fig. 3). All E-2 homozy­
gous subjects demonstrated a slight increase in hepann-
Sepharose-bound cholesterol, however, the mean increase 
just failed to reach significance at any time point In con­
trast, only one out of five non-E-2 and one out of six 
heterozygous E-2 subjects showed an increase in this 
parameter The hepann-Sepharose-bound triglyceride 
serum triglycerides 
(mmol/l ) 
5 -
2 -
6 θ 
time ( hrs ) 
Fig 1 Mean levels ( ± SEM) of serum tnrçlycende concentrations 
before and after a fat load in the non E 2 ( · ) , the heterozygous E 2 (О), 
and the homozygous E 2 (D) groups 
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cholesterol (mmol/l ) -
6 θ 
time (hrs ) 
Fig. 2. Mean levels ( ± SEM) of VLDL + IDL (d<1019 g/ml) 
cholesterol and triglyceride concentrations before and after a fat load in 
the non-E-2 ( · ) , the heterozygous E-2 (O), and the homozygous E-2 (D) 
groups mP<0 0b versus the non-E-2 and the heterozygous groups, 
$ Р < 0 05 versus the heterozygous E-2 group 
concentration at 8 hr was significantly higher in the 
homozygous E-2 group than in both other groups (Fig. 3). 
There were no significant changes in heparm-Sepharose 
unbound cholesterol and triglycerides (Fig. 4). 
cholesterol (mmol/l ) -
Ε о 
= $ = { = { — = } = ? : 
triglycerides (mmol/l) 
¡I 1 
σ 
α 
«ι 
-ι î • i Ä = r i a f c f ^ 
ι — " 1 1 1 1 
О 2 4 6 θ 
time (hrs ) 
Fig. 3. Mean levels ( ± SEM) of heparin-Sepharose-bound cholesterol 
and triglycérides before and after a fat load in the non-E-2 ( · ) , the 
heterozygous E-2 (O). and the homozygous E-2 (Q) groups • /><0 05 
vereus the non-E-2 and the heterozygous groups, \P<0Ô1 venus the 
non-E-2 and the heterozygous E-2 groups 
t о 
triglycerides (mmol/l ) 
Ι ­
Ο 2 4 6 θ 
time (hrs ) 
Fig. 4. Mean levels ( ± SEM) of hepann-Sepharose unbound 
cholesterol and triglycerides before and after a fat load in the non-E-2 
( · ) , the heterozygous E-2 (O), and the homozygous E-2 (D) groups 
" P < 0 05 venus the non-E-2 group 
The mean serum cholesterol and LDL- and H D L -
cholesterol concentrations did not change significantly 
after the fat load In the homozygous E-2 group, the mean 
LDL-cholesterol concentration was significantly lower at 
all time points (Fig. 5). 
Changes in the retinyl palmitate concentra.tions after 
the fat load 
In all groups the mean chylomicron-RP increased after 
the fat load, but, in contrast to a decline in the concentra­
tion of chylomicron-RP between 6 and 8 hr in the non-E-
2 and heterozygous E-2 subjects, there was a continuous 
rise during this time interval in the homozygous E-2 
group (Fig. 6). At 8 hr after the fat load, the mean 
chylomicron-RP concentration was twice as high in the 
latter group (Ρ-Ο.Οΐ). The curves in the heterozygous 
E-2 and the non-E-2 groups were similar. In these latter 
groups the mean heparin-Sepharose-bound-RP showed a 
minimal rise at 5 and б hr after the fat load, followed by 
a slight decline at 8 hr (Fig. 7). The homozygous E-2 
group, however, showed a much greater increase in 
heparin-Sepharose-bound-RP, which still continued to 
rise between 6 and β hr to a level that was nearly four 
times as high as in the two other groups ( P < 0 . 0 1 at 5, 6, 
and 8 hr). In the three groups, there was a slight increase 
of R P in fractions not bound by heparin-Sepharose that 
was twice as high in the homozygous E-2 group as in the 
other groups, but these differences just failed to reach sig­
nificance (Fig. 8) . 
The possible influence of an increased pool size of chy­
lomicrons or V L D L remnants was also studied by per-
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я » 
serum cholesterol 
н-н-н-Н 
HDL-cholesterol 
Î — I T T / 1 î 
LDL-cholesterol 
0 2 4 6 8 0 2 4 6 6 
time (hrs) 
Fig. 5. Mean levels ( ± SEM) of serum cholesterol (chol), HDL- and 
LDL-cholesterol concentrations before and after a fat load in the non-E-
2 ( · ) , the heterozygous E-2 (O), and the homozygous E-2 (D) groups 
'P<0 05 venus the non-E-2 and the heterozygous E 2 groups, {/><() 01 
versus the non-E-2 and the heterozygous E-2 groups 
forming the same fat load studies in three moderately 
hyperhpidemic homozygous E-2 subjects (serum chol-
esterol, 5 35-7 3Θ mmol/1; serum triglycerides, 2.50-3.60 
mmol/I). The changes in the RP concentration in the 
different lipoprotein fractions were comparable to those in 
the normolipidemic E-2 subjects (Fig. 9). 
Study of the transfer of RP from chylomicrons to lipo­
proteins with higher densities in vitro 
The above results on the clearance of chylomicrons and 
their remnants are valid only if there is no significant 
transfer of RP from chylomicrons to other lipoproteins 
in vivo. This possible transfer was studied by incubating 
RP-nch chylomicrons with fasting plasma obtained from 
normolipidemic volunteers with different apoE pheno-
types as described in the Methods section. The levels of 
heparin-bound cholesterol in the E-2 homozygous accep­
tor sera were 0.69 and 0.80 mmol/1, respectively, which 
was more than twice the values in the non-E-2 and the E-2 
heterozygous acceptors. After 5 hr of incubation, 
11.9 ± 1 9 % (mean ± SD) of total RP (range 9 4-14.0%) 
was recovered in the VLDL + IDL and 2 9 ± 0.5% (range 
2.1-3 5%) in the LDL fraction (n - 6). No differences be­
tween the various apoE phenotypes were observed. In the 
incubation experiments (n - 2) with lipoprotein-deficient 
plasma, 12 8% of total RP was found in the VLDL + IDL 
density range and 1 1 % in LDL 
DISCUSSION 
An increase of remnant particles in the plasma, as is 
evident in patients with type III hyperlipoproteinemia 
and in animals fed high cholesterol diets, is closely linked 
with accelerated atherosclerosis Homozygosity for apoE-2 
is thought to be the basic defect in type III hyperlipopro­
teinemia (8, 9, 17) It is of interest to learn whether nor­
molipidemic individuals, who possess the same apoE2/2 
phenotype or who are heterozygous for apoE-2, are able 
to clear remnants normally. If not, they might, at least 
temporarily, be exposed to increased levels of atherogenic 
particles (26). Recently, however, no increased risk was 
found either in homozygous E-2 or heterozygous E-2 sub­
jects in the absence of hypercholesterolemia, and it was 
even suggested that the f2 allele might have a protective 
effect by lowering the LDL-cholesterol (10, 27). Although 
homozygous E2/2 subjects generally are normolipidemic, 
they appear to have a remnant removal defect, because a 
certain amount of cholesterol enriched VLDL (0-VLDL) 
is present, as has been previously published (11, 19, 28, 
29); this was also found in the present study (Table 1). 
Studies in first degree relatives of patients with type III 
6 θ 
t ime ( hrs) 
Fig. 6. Mean levels ( ± SEM) of the retinyl palmitate concentrations in 
the chylomicron fraction (chyl-RP) before and after a fat load in the 
non-E-2 ( · ) , the heterozygous E-2 (O), and the homozygous E-2 (Π) 
groups JP< 0 01 versus the non-E-2 and the heterozygous E-2 groups 
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2 5 
Fig 7 M e a n levels ( ± SEM) of heparin Sepharose bound retinyl 
palmitate ( R P ) concentrations before and after a fat load in the non E 2 
( · ) the heterozygous E 2 ( О ) , and the homozygous E 2 ( О ) groups, 
tP<0 00) vemis the non E 2 and the heterozygous E 2 groups 
hyperlipoproteinemia or in subjects detected by popula 
don studies suggested that a partial removal defect may 
also exist in subjects heterozygous for apoE-2 In some 
studies, cholesterol-enriched VLDL (jS-VLDL) (28, 30, 
31) and apoE concentrations (30) also indicated the pre-
hep unbound- RP (;umol/l ) -
1 δ-
Ι Ο 
0 5 L-
^Jt=&^< 
—ι г 
6 β 
l ime ( hrs ) 
Fig 8. M e a n levels ( ± SEM) of hepann Sepharose unbound retinyl 
palmitate ( R P ) concentrations before and after a fat load in the non E 2 
( · ) , the heterozygous E 2 ( О ) , and the homozygous E 2 ( Π ) groups 
sence of remnants in normolipidemic E-2 heterozygotes 
Others, however, documented only a low value for serum 
cholesterol (11) and low density lipoprotein (LDL) 
cholesterol concentrations (19, 29, 32) In our study, the 
ratio V L D L + IDL cholesterol/serum triglycerides was 
found to be normal (Table 1) 
To study whether the apoE phenotype is an important 
determinant in the removal of chylomicron remnants, we 
used a combination of several techniques for specific de­
termination of these particles during an oral fat load in 
normolipidemic subjects First, a density fraction which 
preferentially may contain the chylomicron remnants was 
prepared by removing the large chylomicrons at the arbi­
trarily chosen centrifugal force of 7, 8 ж ΙΟ9 ξ min and the 
LDL at 1 019 g/1 However, after a fat load, there is a wide 
overlap in density distribution between chylomicrons, 
VLDL, and their remnants Ultracentrifuga! separation 
on the basis of flotation characteristics can only be con­
sidered as a rough measurement of these particles So, ad­
ditionally, we performed hepann-Sepharose chromato­
graphy to isolate VLDL and chylomicron remnants 
Shelburne and Quarfordt (20) discriminated two subfrac-
tions of VLDL, one that was rich in cholesterol and apoE 
and was bound to hepann-Sepharose sind another, poor in 
cholesterol and apoE, that was not bound Nestel et al 
(33) provided evidence that VLDL particles in different 
stages of catabolism can be isolated with hepann-
Sepharose chromatography They found a precursor-pro­
duct relationship between the hepann-Sepharose 
unbound fraction (containing mainly nascent VLDL) 
and the hepann-Sepharose-bound fraction (containing 
mainly chylomicron and VLDL remnants) With this 
method we were also able to separate two subfractions 
with different ratios of VLDL-cholesterol/VLDL trigly­
cerides and apoE/apoC in normal, type III, and type IV 
subjects (Table 2) 
Furthermore, retinyl palmitate was added to the cream 
as a marker of chylomicrons and chylomicron remnants 
In the intestinal mucosal cells, RP is incorporated in the 
apolar core of chylomicrons and remains in the particle 
during transport in the lymphatic and vascular spaces 
After hydrolysis in the capillary beds by lipoprotein-
lipase, chylomicrons are taken up as chylomicron rem­
nants in the parenchymal liver cells (34) In several 
studies the suitability of this method to label chylomicrons 
has been demonstrated (24, 25, 35) A small transfer of 
between 5 and 10% of retinyl esters from chylomicrons to 
lipoproteins with densities higher than 1 019 g/ml has 
been reported in humans in vivo as well as in vitro (24, 
25, 36) Taking into account our in vitro transfer expen-
ments, we found no significant transfer of total RP to 
VLDL + IDL and LDL These results agree well with 
similar in vitro experiments by Berr and Kern (24) 
The total serum triglyceride responses after the oral fat 
load were not significantly different in the E2/2, E3/2, and 
Bmnmkrrutjer et at Gataboliem of cbylomicrons in normolipidemic subjects 
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Fig 9 Mean levels ( ± SEM) of retinyl palmilate (RP) concentrations 
in the chylomicron and the heparin Scpharosc fractions in moderately 
hyperhpidemic E 2/2 subjects (n - 3) after a fat load 
non-E-2 groups It is known that the serum triglyceride 
concentrations after a fat load are also determined by 
other factors, such as the concentration of fasting trigly-
cerides (37) and HDL (38) The three phenotype groups 
had comparable basal serum triglycerides and HDL-
cholesterol concentrations In hyperhpidemic subjects 
with the apoE2/2 phenotype, a normal lipoprotein lipase 
activity has been reported (39) and a normal conversion 
of large VLDL (Sf 100-400) to smaller particles (Sf 
20-60) (40) Nevertheless, a special class of chylomicron-
hke particles present in the VLDL fraction of patients 
with type III hyperlipoproteinemia has been shown to be 
resistant to hpolysis in vitro, that was found to be caused 
by the absence of the normal apoE-3 or E-4 (41, 42) In 
our study, the similar triglyceride responses in total serum 
and in the chylomicron fraction suggest that in normohpi-
demic subjects the initial hydrolysis of chylomicrons is in-
dependent of the apoE phenotype Only slight effects of 
the fat load on the lipid concentrations were seen in the 
heparin Sepharose fractions This could be a consequence 
of the in- and outflow of a wide spectrum of partially deh-
pidated particles, with no net differences of lipid concen-
trations in these fractions 
The results of the RP measurements in the different 
fractions are more informative A persistent rise in 
chylomicron-RP was seen between 6 and 8 hr in the 
homozygous E-2 subjects (Fig 6) Plasma triglycerides 
had already decreased at this time, which indicates a nor-
mal initial hydrolysis of chylomicron triglycerides but a 
delay in removal of partially degraded chylomicrons or 
remnants This is also evident from the persistent rise of 
RP in the remnant fraction isolated by hepann 
Sepharose In contrast, the chylomicron-RP in the hetero-
zygous E 2 subjects showed a decrease within 8 h after the 
fat load (rig 6) At 8 hr similar chylomicron-RP concen-
trations were measured and compared with the non-E 2 
group In addition, the pattern of the RP concentration 
in the heparm-bound fraction (Fig 7) appeared to be 
highly comparable with that observed in the non-E-2 
group Furthermore, the retinyl palmitate/tnglycendes 
ratios in the chylomicron and the heparm-bound fractions 
at 8 hr were comparable in the non-E-2 and E-2 heterozy-
gous groups (5 7 ±2 1 and 0 8 ± 0 5 v s 4 5 ± 1 7 and 
1 3 ± 1 2, respectively) but were distinctly lower in com-
parison with the E 2 homozygotes (11 9 ± 5 6 and 
3 7 ± 1 4) Therefore, the conclusion that in E-2 heterozy-
gotes the clearance of chylomicron remnants is normal is 
justified even when the removal mechanism is challenged 
by a fat load 
Results similar to those in the normohpidemic E2/2 
subjects were obtained in moderately hyperhpidemic 
E2/2 subjects (Fig 9), which demonstrates that the distri-
bution of RP is not affected by the pool size of the rem-
nant particles Our results agree well with the report by 
Hazzard and Bierman (35) who gave vitamin A-
containing oral fat loads to patients with type III and type 
IV hyperlipoproteinemia and found that the removal of 
chylomicron remnants was delayed in type III patients, as 
was indicated by a slow disappearance rate of vitamin A 
in the Sf 20-30 fraction Our study is an extension of this 
observation to normohpidemic E2/2 subjects 
Recently, Stalenhoef et al (43, 44) described studies us-
ing a different approach to investigate separately the 
metabolism of chylomicrons, VLDL, and their remnants 
They injected nascent chylomicrons and large VLDL, ob-
tained from a donor with lipoprotein lipase deficiency, 
and followed the removal of radiolabeled intestinal apoB 
48 and hepatic apoB-100 in normal individuals and in 
three subjects with type III hyperlipoproteinemia, one of 
whom was normohpidemic at the time of the study The 
removal of apoB-48 (and apoB-100) was markedly and 
comparably delayed in all three E2/2 subjects, even in the 
one with normal lipid levels This finding again supports 
our results in normohpidemic homozygous E-2 subjects 
and also suggests that the clearance of VLDL remnants 
is delayed in these subjects 
We conclude from our in vivo studies that, in normoli-
pidemics, the presence of two c2 alleles, which determines 
the apoE phenotype E2/2, leads to a temporary accu-
mulation of chylomicron remnants up to 8 hr after a fat 
load, while the presence of one €2 allele, which determines 
the E-2 heterozygous apoE phenotypes, apparently does 
not affect the catabohsm of chylomicron remnants 10 
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SUMMARY 
The role of the apo E polymorphism in the removal of remnants of very 
low density lipoproteins and chylomicrons was studied after a carbo-
hydrate-rich diet in 10 healthy normolipidemic volunteers with dif-
ferent apo E phenotypes during 7 days. The cholesterol concentration 
in the hepann-sepharose bound part of the VLDL+IDL fraction (d<1.019 
g/ml) was taken as an estimate of the remnant concentration. Before 
and after carbohydrate-rich diet retinyl palmitate, mixed with cream, 
was consumed by each subject the evening before the fasting venepunc-
ture to quantify the removal of chylomicron remnants. After the diet 
there was a comparable mean rise in the three groups in serum and in 
very low density lipoprotein triglycerides of about 30Sí and 50%, 
respectively. The concentration of remnants of very low density lipo-
proteins increased slightly in all subjects. The concentration of 
retinyl palmitate in the d<1.019 g/ml fraction was 20% lower than 
before this diet in the E-2 homozygous subjects. In the other two 
groups, however, 25 to 80% higher retinyl palmitate levels were 
found. It is concluded, that after a carbohydrate-rich diet there is 
only a slight increase of very low density lipoprotein remnants, inde-
pendent of the apo E polymorphism. The removal of chylomicron rem-
nants, however, seems to be facilitated in E-2 homozygous subjects, in 
contrast to a slower removal in the groups with other apo E pheno-
types. 
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INTRODUCTION 
Apolipoprotein (apo) E plays a majof role in the metabolism of rem-
nants of chylomicrons and very low density lipoproteins (VLDL). As a 
surface component of these particles, it is a high affinity ligand for 
specific lipoprotein receptors on the hepatocytes (1,2). With isoelec-
tric focusing of VLDL apoproteins three major isoforms of apo E (E-4, 
E-3, E-2) can be distinguished (3,4). The synthesis of these isoforms 
is regulated by three co-dominant alleles on one polymorphic genetic 
locus (5). Homozygotes for these alleles (apo E phenotypes E3/3, E4/4 
and E2/2) have only one of these major isoforms, whereas heterozygotes 
(apo E phenotypes 4/3, E3/2 and E4/2) two. The allele coding for apo 
E-3 is most frequent in the general population (75-80%) (5-8). Exten-
sive studies in patients with type III hyperlipoproteinemia have re-
vealed, that homozygosity for apo E-2 represents the genetic substrate 
for this inherited disturbance in lipoprotein metabolism (9). It has 
been found, that apo E-2 is not properly recognized and therefore 
poorly bound by the apo E and B,E receptors (2,9-12), thus leading to 
an accumulation of lipoprotein remnants and subsequently to early 
atherosclerotic disease. Nevertheless, only 1% of the subjects with 
the E2/2 phenotype develops type III hyperlipoproteinemia, because ad-
ditional metabolic disturbances, increasing the VLDL production, are 
required for its full expression (13). Therefore, most E2/2 subjects 
are normolipidemic, although their apo E-2 is just as abnormal as in 
type III patients (14). They also accumulate remnants both in the 
postabsorptive state (6) and after a fat load (15). In E-2 heterozy-
gous subjects where the apo E-2 isoform is concomitantly present with 
the E-3 or E-4 isoform, a partial removal defect of remnants may be 
expected. Indeed, heterozygosity for apo E-2 appeared to be infre-
quently associated with type III hyperlipoproteinemia (5,13,16) and 
also in a minority of normolipidemic subjects with this phenotype ß-
VLDL was demonstrated (13). In a previous study, however, we found in 
an 8 hour observation no accumulation of chylomicron remnants after a 
fat load in E-2 heterozygotes (15). 
The present study was undertaken to investigate the influence of the 
apo E polymorphism on the removal of remnants derived from VLDL. For 
this purpose the synthesis of VLDL was stimulated by a carbohydrate 
(CHO)-rich, low fat diet with additional alcohol to challenge the re-
ceptor dependent removal capacity for VLDL remnants. Furthermore, the 
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clearance of chylomicrons and their remnants was estimated before and 
after this diet, using retinyl palmitate (RP) as a marker. 
MATERIALS AND METHODS 
Subjects and study protocol 
Ten healthy normolipidemic volunteers (Table 1) participated in the 
study after they had given informed consent. All were male hospital 
workers or medical students, who were screened for their apo E pheno-
type and serum lipid concentrations. Three apo E phenotype groups were 
distinguished: 1) the homozygous E-3 group (E-3 HOZ), including four 
subjects with apo E phenotype E3/3; 2) the heterozygous E-2 group (E-2 
HEZ) consisting of four subjects, three with the E3/2 and one with the 
E4/2 apo E phenotype; 3) the homozygous E-2 group (E-2 HOZ; 2 sub-
jects) . 
Table 1 Characteristics of the participating subjects 
Subjects Age (yrs) Weight (kg) Height (cm) Rel. Weight (%) 
H0Z*E-3 
1. 38 
2. 32 
3. 37 
4. 23 
HEZ E-2 
1. 24 
2. 37 
3. 23 
4. 24 
HOZ E-2 
1. 20 
2. 35 
*H0Z: Homozygous 
HEZ: Heterozygous 
^Metropolitan Life Insurance Company Tables 1983. 
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71.5 
73.0 
82.6 
68.0 
178 
177 
178 
187 
102.3 
105.5 
118.2 
88.5 
79.9 
69.0 
80.1 
64.9 
177 
180 
185 
183 
115.5 
96.6 
106.5 
88.1 
72.0 
62.2 
181 
168 
100.3 
101.0 
All subjects were studied on an outpatient basis. They were neither 
overweight, nor did they take any medication or excessive amounts of 
alcohol. From each subject a dietary history was recorded and the 
caloric intake was estimated using current food tables. In the week 
preceeding the study they consumed their habitual diet consisting of 
about ISS of protein, 50л of carbohydrates and 355ί of fat (as percen­
tage of total calories). During the CHO-nch diet period of 7 days, 
most fat was isocaloncally replaced by carbohydrates, resulting in a 
composition of ISA of protein, B0% of carbohydrates and 5й'of fat. Ad­
ditionally 30 g of alcohol had to be consumed every day. Subjects 
were asked to keep a food diary to check their intake. Differences in 
body weight before and at the end of the diet period were limited to a 
maximum of 0.5 kg. Blood samples for determination of serum lipids 
were taken by venepuncture after an overnight fast on two consecutive 
days prior to and at the end of the CHO-nch diet and were stored in 
the dark by 4 0 C with nitrogen. On the evening before the start and at 
the end of the CHO-nch diet 150,000 I.U. of retinyl palmitate, mixed 
with 50 g of cream, were given and the RP concentration was measured 
the following morning to study the chylomicron catabolism. 
Analytical Methods 
From each sample 3 ml of serum was transferred in an ultracentrifuge 
tube with D2O; the density was then raised to d=1.019 g/ml. VLDL+IDL 
were isolated by ultracentrifugation for 16 hrs. at 40,000 rpm. in the 
I.E.G. B-60 ultracentrifuge (Damon I.E.G., Needham Heights, Mass., 
U.S.A.), using the I.E.G. fixed angled rotor no. 468. The concentra­
tion of remnants was estimated by hepann-sepharose chromatography of 
the VLDL+IDL fraction according to Shelburne and Quarfordt (15,17), 
which resulted in two subfractions. The cholesterol concentration in 
the heparin bound fraction was used as an estimate for the total rem­
nant concentration. 
HDL-cholesterol was determined by the polyethylene-glycol 6000 method 
(18). Cholesterol and triglycerides were determined enzymatically 
with a centrifugal analyzer (Multistat III). LDL-cholesterol was cal­
culated by subtracting HDL-cholesterol from the cholesterol content in 
the d>1.019 g/ml fraction. Apo E phenotyping was performed after iso­
electric focusing of the VLDL apoproteins (19). Apoprotein В and E in 
total serum were determined in quadruplicate by radial immunodiffusion 
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Table 2 Effects of carbohydrate-rich diet on serum and lipoprotein lipids (mmol/1) 
Subjects 
H0Z*E-3 
1. 
2. 
3. 
4. 
X + SD 
HEZ E-2 
1. 
2. 
3. 
4. 
X + SD 
Du 
A 
В 
A 
В 
A 
В 
A 
В 
A 
В 
A 
В 
A 
В 
A 
В 
A 
В 
A 
В 
Btt 
4 
4 
4 
3 
chol 
5.63 
4.22 
3.82 
3.28 
5.51 
4.82 
4.94 
3.72 
.98+0. 
.01+0. 
4.13 
3.37 
6.26 
4.80 
3.58 
3.17 
4.63 
3.91 
.65+1. 
.81+0. 
serum í 
83 
66 
16 
73 
1. 
1, 
1, 
1. 
TG 
1.09 
1.34 
0.73 
0.76 
1.28 
2.27 
1.18 
1.85 
.07+0.25 
.56+0.65 
1.26 
1.34 
1.05 
1.40 
1.22 
1.14 
0.93 
1.38 
.12+0.15 
.32+0.12 
0 
0 
0 
0 
VLDL 
Chol 
0.64 
0.60 
0.28 
0.33 
0.61 
0.87 
0.55 
0.80 
.52+0. 
.65+0. 
0.57 
0.64 
0.47 
0.79 
0.53 
0.48 
0.44 
0.65 
.50+0. 
.64+0. 
16 
24 
06 
13 
+IDL 
0, 
1. 
0, 
0, 
TG 
0.68 
0.94 
0.40 
0.48 
0.98 
1.91 
0.70 
1.42 
.65+0.25 
.19+0.62 
0.82 
1.01 
0.59 
1.03 
0.84 
0.83 
0.44 
0.88 
.67+0.19 
.94+0.10 
0. 
0. 
0, 
0, 
R§ 
0.59 
0.45 
0.38 
0.44 
0.47 
0.38 
0.47 
0.43 
.48+0.09 
.43+0.03 
0.46 
0.48 
0.44 
0.57 
0.43 
0.42 
0.49 
0.47 
,46+0.03 
.49+0.06 
3. 
2. 
2. 
2. 
LDL 
chol 
3.77 
2.56 
2.29 
1.88 
3.91 
3.07 
3.25 
2.33 
,31+0.73 
,46+0.50 
2.71 
2.00 
3.93 
2.82 
1.88 
1.83 
2.99 
2.10 
.88+0.85 
.19+0.44 
HDL 
chol 
1.37 
1.07 
1.20 
1.06 
1.02 
0.73 
1.16 
0.85 
1.19+0.14 
0.93+0.17 
0.86 
0.77 
1.72 
1.36 
1.16 
1.01 
1.30 
1.06 
1.26+0.36 
1.05+0.24 
HOZ E-2 
1. 
X + SD 
A 
В 
А 
В 
А 
В 
3.11 
2.77 
3.68 
3.36 
3.40+0. 
3.07+0. 
,40 
.42 
1 
1 
1.26 
1.52 
1.28 
1.57 
.27+0.01 
.55+0.04 
1 
1 
0.80 
1.01 
1.19 
1.39 
.00+0. 
.20+0. 
28 
27 
0, 
1, 
1.01 
1.42 
0.93 
1.21 
.97+0.06 
.31+0.15 
0, 
0, 
0.63 
0.67 
0.96 
0.89 
,80+0.23 
.78+0.16 
1, 
0, 
1.11 
1.02 
1.30 
0.89 
.21+0.13 
.96+0.09 
1 
1 
1.14 
0.87 
1.11 
1.15 
.13+0.02 
.01+0.20 
HOZ: homozygous 
HEZ: heterozygous 
"^values before (A) and after carbohydrate-rich diet. (B) 
(mean of two values) 
*Chol: cholesterol 
TG: triglycerides 
§Ratio VLDL+IDL chol/serum TG 
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in 0.8л agarose in barbital buffer, pH=B.6. The results agreed well 
with those obtained by a rocket immuno electrophoresis method (20), 
both for normal and hypertnglycendemic sera. Treatment with the de­
tergent Tween 20 (21) did not improve the immunoreactivity. Interassay 
coefficients of variation were between 5.1 and 6.850 (n=12). Retinyl 
palmitate in the VLDt+IDL fraction was measured by an HPLC assay (15). 
RESULTS 
The effects of the CHO-nch diet on the levels of serum lipids, lipo­
protein lipids and apoproteins are summarized in tables 2 and 3. For 
each subject the values after the basal diet and after the CHO-nch 
diet are given as the mean of two fasting blood samples, taken on two 
consecutive days. The E-2 HOZ group had lower mean basal levels for 
serum cholesterol and LDL-cholesterol (Table 2), whereas the levels 
for VLDL+IDL-cholesterol and hepann-bound cholesterol (Table 3) were 
higher than in both other groups. The CHO-nch diet reduced serum 
cholesterol and LDL-cholesterol by 10 to 20SÍ and 20 to 255», respect-
ively, in all groups (Table 2). Serum triglycerides increased by 46л 
in the E-3 HOZ subjects, which was mainly caused by a rise in two of 
the four subjects (Table 2). Three of the four E-2 HEZ subjects showed 
a rise in serum triglycerides causing a mean increase of 18« in this 
group. In the E-2 HOZ group there was a similar increase of 225». The 
changes in serum triglycerides were mainly due to changes in the VLDL-
+IDL-fraction (Table 2). The increase in VLDL+IDL-cholesterol was com-
pararable in all groups, ranging from 20% (E-2 HOZ) to 28?ó (E-2 HEZ; 
Table 2). This rise can be ascribed in part to an increase in remnant 
particles as can be derived from the cholesterol content in the hepa-
rin bound fraction (Table 3). There were no clear differences in the 
increase in the total remnant concentration between the groups. The 
VLDL+IDL-chol/serum-TG ratio remained unchanged during the CHO-nch 
diet (Table 2). HDL-cholesterol decreased about 225» in the E-3 HOZ 
group, 175Í in the E-2 HEZ group and 115Í in the E-2 HOZ group. 
During the basal diet the apo В concentrations were low in the E-2 
HOZ, intermediate in the E-2 HEZ group and highest in the E-3 HOZ sub­
jects. The opposite was found for the apo E concentrations with high 
levels in the E-2 HOZ group and low levels in the HOZ E-3 group. After 
the CHO-nch diet there was a small decrease in apo В in all groups. 
Apo E declined slightly in the E-2 HOZ and E-2 HEZ groups, but not in 
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Table 3 Effects of carbohydrate-rich diet on heparin bound (HB) 
Subjects 
H0Z*E-3 
1. 
2. 
3. 
4. 
X + SD 
HEZ E-2 
1. 
2. 
3. 
4. 
X + SD 
HOZ E-2 
1. 
2. 
Χ + SD 
cholesterol 
diet+ 
A 
В 
A 
A 
A 
В 
A 
В 
A 
В 
A 
В 
A 
В 
A 
В 
A 
В 
A 
В 
A 
В 
A 
В 
A 
В 
and apopro 
HB * 
Chol 
0.32 
0.42 
0.21 
0.25 
0.39 
0.45 
0.41 
0.53 
0.33+0. 
0.41+0. 
0.26 
0.39 
0.33 
0.56 
0.30 
0.35 
0.31 
0.48 
0.30+0. 
0.45+0. 
0.51 
0.70 
0.82 
0.92 
0.67+0. 
0.81+0. 
items 
09 
12 
03 
09 
22 
16 
В and E (mg/l) 
apo В 
1119 
984 
950 
915 
1598 
1687 
1133 
947 
1200+278 
1133+370 
1028 
785 
1165 
935 
583 
659 
1010 
1013 
947+252 
848+158 
521 
420 
633 
541 
577+79 
481+86 
apo E 
44 
44 
30 
29 
38 
36 
44 
42 
39+7 
38+7 
72 
59 
102 
80 
63 
56 
77 
69 
79+17 
66+11 
156 
120 
95 
79 
126+43 
100+29 
*H0Z: homozygous 
HEZ: heterozygous 
tvalues before (A) and after carbohydrate-rich (В) diet 
(mean of two values) 
^chol: cholesterol 
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the E-3 HOZ subjects. Before as well as after the CHO-diet the highest 
RP concentrations were found in the E-2 HOZ group after a small RP 
containing fat load on the previous evening. However, the RP response 
was about 22?» lower in the E-2 HOZ subjects after the CHO-nch diet, 
whereas RP concentrations were 78X and 30S higher in both other groups 
after the CHO-diet, respectively. 
RP-VLDL* I D U p m o l / l ) 
x t SD 
3 -
1 -
• basal diet 
ES CHO-nch diet I 
HOZ 
E-3 
HEZ 
E-2 
HOZ 
E-2 
Fig. 1 Mean values + SD of retinyl palmitate (RP) in the VLDL+IDL 
fraction (d<1.019 g/ml) in the homozygous E-3 (HOZ E-3), the 
heterozygous E-2 (HEZ E-2) and the homozygous E-2 (HOZ E-2) 
groups 11 hrs after a RP load (mixed with 50 g of cream) 
during the basal diet (day 1) and the carbohydrate (CHO)-rich 
diet (day 8). 
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DISCUSSION 
The present study was primarily focused on a possible role of the apo 
E polymorphism on the catabolism of remnants of intestinal and hepatic 
origine after a CHO-nch diet with an additional amount of alcohol. 
This type of diet is known to induce the synthesis of VLDL triglyce­
rides in the liver (22,23) and may cause a rise in the number of VLDL-
remnants, if there is a remnant removal defect at the same time. Be­
cause remnant particles cannot be separated from newly secreted VLDL 
merely on account of flotation characteristics, we performed hepann-
sepharose chromatography of the d<1.019 g/ml fraction to measure the 
remnant concentration. On agarose electrophoresis the heparin bound 
fraction showed a mobility between pre β and β which is characteristic 
for remnant particles (15,17) (results not shown). RP, suspended in a 
small amount of cream (17.5 g of fat), was given to each subject to 
study the removal of chylomicrons and their remnants overnight. During 
the lipolytic conversion of chylomicrons to chylomicron remnants, RP 
remains in the particle until uptake in the liver and is therefore a 
suitable marker for chylomicron metabolism (24,25). In previous expe­
riments we did not find a significant transfer of RP to lipoproteins 
with higher densities (15). The changes in the levels of serum lipids 
and lipoproteins (an increase in serum triglycerides and a decrease in 
serum and LDL-cholesterol), caused by the CHO-nch diet as reported 
here, are in agreement with other studies (22,26,27). The rise in 
serum triglycerides was, despite of considerable inter-individual 
variation, comparable in the three groups. This rise could be mostly 
attributed to an increase in VLDL triglycerides and is most likely 
caused by an increase in the rate of hepatic VLDL synthesis (22). 
Besides an increase in number, VLDL particles become larger in diame­
ter because of higher amounts of triglycerides per particle (26). In 
part, this increase in VLDL triglycerides could also have been caused 
by changes in lipoprotein lipase activities. A decline of about 505» in 
muscle lipoprotein lipase was demonstrated during a CHO-nch diet 
during 3 days in normolipidemic men (28). Furthermore, Goldberg et 
al. reported recently an acute inhibition of hepatic lipase after 
alcohol intake (29). Although the number of the investigated subjects 
was small, it is clear that the VLDL-triglycerides increased much less 
in the E-2 HOZ subjects than in the E-3 HOZ subjects, but comparably 
in the E-2 HEZ subjects. 
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This 7 days lasting CHO-nch diet with additional alcohol caused in 
general only a slight increase in the concentrations of remnants in 
all subjects as represented by the heparin bound cholesterol. More­
over, there was a small decline of apo E levels in total serum. Nor­
mally, an increased number of remnants is associated with elevated apo 
E concentrations (30). Thus, in normolipidemics with different apo E 
phenotypes the removal of VLDL remnants is not seriously affected by 
an increased VLDL-production. This might be caused by an upregulation 
of the B,E receptors, because of the low cholesterol content of the 
CHO-nch diet, so that the removal of the higher number of VLDL rem­
nants has become more efficient. 
Together with a rise in VLDL cholesterol, there was a decrease in LDL 
cholesterol to the same extent in all groups. Next to the low choles­
terol intake with upregulation of apo B,E receptors with an increased 
removal of LDL, there may be also less conversion of larger VLDL par­
ticles to LDL (31,32). 
Of interest were the findings by Vessby and Carlson (33), who reported 
that by a CHO-nch diet the type III hyperlipoproteinemia was convert­
ed into a type IV hyperlipoproteinemia, because p-VLDL disappeared on 
agarose electrophoresis. This was mainly caused by a decrease in the 
concentration of chylomicron remnants in the plasma. We also studied 
the removal of chylomicron remnants overnight prior to and at the end 
of the diet, using RP as a marker of chylomicron remnants. As we ob­
served in a previous study (15), their removal was impaired in the E-2 
HOZ group in comparison with both other groups. However, after the 
carbohydrate-rich diet in both E2/2 subjects the removal was about ΖΟΛ 
faster than before the diet. In contrast, three out of four E-3 HOZ 
and all E-2 HEZ subjects demonstrated a slower removal of chylomicron 
remnants after the CHO-nch diet. We assume that during such a low fat 
diet the removal of chylomicron remnants by the apo E receptors in E-2 
HOZ subjects has become more efficient as a result of the decreased 
pool size of chylomicron remnants. 
In summary the present findings indicate that by a carbohydrate-rich 
diet with supplementary alcohol intake, only a small increase of VLDL 
remnants is generated and the degree of this increase is independent 
of the apo E polymorphism. The removal of chylomicron remnants, how­
ever, seems to be increased in E-2 HOZ subjects by this diet. This is 
not the case in E-3 HOZ and in E-2 HEZ subjects who show a slower 
removal. 
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SUMMARY 
The relation between the apo E phenotype and the response to dietary 
cholesterol of serum lipoproteins was studied in 3 normolipidemic sub-
jects with apo E phenotype E3/3, 3 with E3/2, 3 with E4/3, 2 with E V 4 
and in 3 with apo E phenotype E2/2. During 8 days a high cholesterol 
(1800 mg) and high saturated fat (P/5=0.2) diet was consumed. After 
the cholesterol-rich diet a significant 20% increase was found in the 
mean levels of cholesterol in total serum, very low density + inter-
mediate density lipoproteins (VLDL+IDL) and low density lipoproteins 
(LDL), accompanied by a 13% rise in high density lipoprotein (HDL) 
cholesterol. The mean increments of serum cholesterol and LDL-chol-
esterol were similar in all apo £ phenotype groups. An increase in 
serum cholesterol of more than 1 mmol/l was only found in two E2/2 
subjects. In the E2/2 group a rise in VLDL+IDL-cholesterol was found, 
in contrast to the other groups, which was largely due to an increase 
in the concentrations of remnants of triglyceride-nch lipoproteins 
(hepann-bound cholesterol). Two subjects could be identified who 
responded hardly or not to the increase in dietary cholesterol ("hypo-
responders"), one with apo E phenotype E3/2 and one with E4/3. 
At the end of the cholesterol-rich diet an oral fat load (50 g fat/m2 
as cream + 500 mg chol) with 150,000 I.U. retinyl palmitate was given 
to study the disappearance of chylomicron remnants. Only in the E2/2 
group there was a delay in the disappearance of retinyl palmitate from 
the chylomicron fraction and the heparin unbound and bound portions of 
the VLDL+IDL fraction 8 and 24 hrs after the fat load; this delay was 
even more pronounced than under basal conditions. 
The results suggest, that during a cholesterol-rich, high saturated 
fat diet: 1. in normolipidemic subjects the apo E phenotype E2/2 
differs from the other phenotypes by an accumulation of remnants; 2. 
the rise in LDL-cholesterol levels is independent of the apo E poly-
morphism; 3. in the E2/2 subjects the clearance of chylomicron rem-
nants seems to be even more delayed than during a normal diet. There-
fore normolipidemic E-2 homozygous subjects consuming a high chol-
esterol and high saturated fat diet may have a higher atherosclerotic 
risk than subjects with the other apo E phenotypes. 
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INTRODUCTION 
Apolipoprotein E (apo E) is involved in the receptor dependent cata-
bolism of remnants of very low density lipoproteins (VLDL), chylomi­
crons and high density lipoproteins (HDLC) (1,2). There are three 
major isoforms of apo E: apo E-2, E-3 and E-4, coded by three co-domi­
nant alleles on one genetic locus (3,4). These isoforms can be deter­
mined by isoelectric focusing of VLDL apoproteins (3). Nearly all 
patients with type III hyperlipoproteinemia are homozygous for the e2 
allele that codes for apo E-2. In vivo (5) as well as in vitro (6-B) a 
strongly reduced affinity of this apo E isoform for apo E and B,E re­
ceptors is demonstrated compared to apo E-3. On the other hand, apo 
E-4 is metabolized faster than apo E-3 by these receptors (9). In 
studies of large populations (10-12) and patients with hyperlipidemia 
(13,14) the ε2 allele has been associated with elevated serum trigly­
ceride and lower serum cholesterol levels, whereas the eA allele 
appears to have an increasing effect on serum cholesterol. It has been 
speculated that these small effects of the ε2 and e4 alleles on serum 
lipid and lipoprotein levels may be caused by a regulatory effect on 
the number of B,E receptors by E-2 and E-4 containing triglyceride-
rich lipoproteins (9,15). 
Studies in rabbits (16) and also in hunans (17), have indicated that 
an increase in dietary cholesterol can reduce the number of B,E recep­
tors by 50-605o. Nevertheless, the individual response to dietary chol­
esterol may show a large variation (18).The main object of the present 
study was to find out, whether the apo E polymorphism underlies this 
variation. Furthermore, the influence of this diet on the clearance of 
chylomicrons was studied by performing oral fat loads with retinyl 
palmitate, according to a previously described procedure (19). 
MATERIALS AND METHODS 
Subjects and study protocol 
The study was conducted in 14 healthy normolipidemic young male volun­
teers (Table 1), after they had given informed consent. They were 
either hospital personnel or medical students and were selected to 
participate on account of their apo E phenotype. Four apo E phenotype 
groups were formed: the E3/3 (n=3), the E3/2 (n=3), the E4/4-3 (two 
E4/4 and three E4/3 subjects) and the E2/2 group (n=3). 
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Table 1 Characteristics of the participating subjects. 
Subjects 
ЕЭ/3 
1 . 
2. 
3. 
E3/Z 
1 . 
2. 
3. 
E4/4-3 
1 . 
2. 
3. 
4 . 
5. 
E2/2 
1 . 
2. 
3. 
Age ( у г з . ) 
32 
за 
23 
29 
37 
24 
23 
25 
26 
33 
37 
24 
21 
36 
Weight (kg) 
73.7 
73.4 
70.3 
63.2 
68.1 
82.6 
67.2 
71.5 
66.6 
78.4 
73.2 
81.1 
72.1 
65.0 
Height (cm) 
178 
178 
187 
180 
178 
177 
185 
186 
184 
176 
180 
187 
181 
183 
The E2/2 subjects were not related to a known patient with type III 
hyperlipoproteinemia. 
The study took place on an outpatient base. They were all non-smokers 
and not overweighted and none of them was taking excessive alcohol or 
used any medication. They were on a normal western diet, consisting of 
50 energy % of carbohydrates, 35Ä of fat and ISS of protein. The week 
before the start of the cholesterol-rich diet the subjects were on 
their habitual diet, but were asked to avoid food products rich in 
cholesterol and saturated fat. In this way the cholesterol intake was 
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kept below 200 mg/day, whereas the P/S ratio was about 0.7. During the 
study period of eight days 3 boiled eggs and 3 egg yolks were added to 
the habitual diet to increase the daily cholesterol intake to 1800 
mg. Moreover, the relative amount of saturated fat was enlarged, by 
which the P/S ratio declined from 0.7 to 0.2. As a consequence, the 
relative amount of dietary fat increased from 35 to about 4555 of the 
24 hr caloric intake at the expense of carbohydrates. Subjects kept 
their alcohol intake the same throughout the study with a maximum of 
two consumptions per day. Adherence to the diet was checked by a 48 hr 
dietary recall. The body weight did not change during the cholesterol-
rich diet (71.9+5.8 versus 71.8+5.8 kg (mean +_ SD)). Fasting blood 
samples were taken by venepuncture into vacutainer tubes on two conse-
cutive days just before and on the last two days of the cholesterol-
rich diet. 
At the end of the study after an overnight fast an oral fat load, con-
sisting of cream (50 g fat/m ) and two egg yolks, was given to each 
subject. Retinyl palmitate was added to the cream as a marker of chy-
lomicrons and their remnants as reported previously (19). Blood sam-
ples were taken at 4, 8 and 24 hr after the fat load, while the sub-
jects were kept fasting during 8 hours. 
Analytical Methods 
The preparation of the lipoproteins and apoproteins was performed as 
reported previously (19). The serun was separated within 3 hours after 
venepuncture by low speed centrifugation for 15 min. The density of 5 
ml of serum was raised to 1.019 g/ml with DJ) and subsequently the 
VLDL+IDL fraction was isolated by ultracentrifugation. Only after the 
fat load the chylomicron fraction was isolated first at d<1.006 g/ml 
by ultracentrifugation for 30 min at 14,000 rpm. Heparin-Sepharose 
chromatography (19,20) and cumulative rate ultracentrifugation (19,21) 
were used to estimate the total concentration of remnants of the 
d<1.019 g/ml fraction (heparin bound cholesterol and Sf 20-100 chol-
esterol respectively). HDL-cholesterol was determined in whole serum 
by the polyethylene-glycol 6000 method (22). LDL-cholesterol was cal-
culated by subtracting HDL-cholesterol plus VLDL+IDL cholesterol from 
total cholesterol. Total cholesterol and triglycerides were determined 
automatically (Multistat) by enzymatic kits (19). 
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Table 2 Mean levels of serum lipids, lipoproteins (mntol/L +SD) and 
apoproteins (mg/L +SD) before (A) and after (B) the chol­
esterol-rich diet in E3/3, E3/2, Ε4Λ-3 and E2/2 subjects. 
Diet 
E3/3 
(n=3) 
E3/2 
(n=3) 
Ε4Λ-3 
(n=5) 
E2/2 
(n=3) 
Serum Choi. A 4.33+0.69 4.74+1.10 
В 5.21+0.91 5.35+1.37 
4.55+0.63 2.89+0.72 
5.19+0.79 3.82+0.53 
Serum TG 
VLDL+IDL-chol 
VLDL+IDL-TG 
Heparin bound-
Sf 20-100 chol 
1 
chol 
A 
В 
A 
В 
A 
В 
A 
В 
A 
В 
0.90+0.39 1.01+0.26 
0.87+0.48 0.88+0.12 
0.38+0.19 0.61+0.22 
0.49+0.19 0.53+0.19 
0.53+0.37 0.66+0.21 
0.52+0.12 0.53+0.09 
0.31+0.15 0.45+0.20 
0.34+0.20 0.37+0.10 
0.36+0.16 0.54+0.18 
0.41+0.21 0.49+0.17 
0.95+0.25 0.98+0.22 
0.90+0.21 1.20+0.47 
0.44+0.07 0.73+0.26 
0.44+0.09 1.03+0.07 
0.54+0.28 0.77+0.14 
0.50+0.17 0.98+0.13 
0.33+0.07 0.64+0.36 
0.31+0.06 0.74+0.07 
0.42+0.08 0.67+0.24 
0.42+0.07 0.B2+0.07 
HDL-chol 
LDL-chol 
A 1.15+0.17 1.11+0.15 
В 1.39+0.11 1.44+0.46 
A 2.79+0.61 2.92+0.73 
В 3.34+0.79 3.24+0.92 
1.16+0.14 1.06+0.14 
1.25+0.20 1.15+0.18 
3.06+0.75 1.13+0.31 
3.42+0.66 1.65+0.37 
VLDL+IDL-
apo В 
apo E 
-chol/serum TG A 
В 
A 
В 
A 
В 
0.42+0.11 
0.60+0.14 
1029+196 
1172+213 
56+13 
57+ θ 
0.60+0.10 
0.74+0.22 
1164+378 
1196+351 
86+15 
B4+20 
0.47+0.09 
0.50+0.10 
1108+221 
1217+491 
47+26 
53+31 
0.65+0.17 
0.85+0.21 
447+105 
634+78 
102+42 
107+35 
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Apo E phenotyping was performed by one-dimensional isoelectric focus­
ing of the VLDL+IDL apoproteins and subseguent densitometric scanning 
(23,24). Apo В and E in total serum were determined in quadruplicate 
by radial immunodiffusion in 0.8% agarose in Veronal buffer, pH=8.6 
(25). Monospecific antibodies against these apoproteins were raised in 
rabbits (apo B) and in a sheep (apo E ) . 
Statistics 
All data are given as mean + SD, unless otherwise indicated. The data 
prior to and after the cholesterol-rich diet were compared by 
Student's t-teat for paired samples. Comparisons between apo E pheno-
type groups were made by the 2-tailed Student t-test. Ρ values under 
5SS were considered significant. 
RESULTS 
Changes in serin lipids, lipoproteins and apolipoproteins by the chol­
esterol-rich diet 
The pre-diet values for serum lipids and lipoproteins were similar in 
the E3/3 and E4/4-3 groups (Table 2; Fig. 1). Both the E3/2 and the 
E2/2 groups had comparable triglyceride levels, but elevated levels of 
VLDL+IDL cholesterol and a higher ratio of VLDL+IDL cholesterol/serum 
triglycerides compared to the other groups. Furthermore, the LDL chol­
esterol concentration was lower in the E2/2 subjects. The apo E levels 
were higher in the E3/2 and E2/2 subjects, whereas apo В levels were 
low in the E2/2 subjects in comparison with the other groups. 
The cholesterol-rich diet caused a mean increase in total serum chol­
esterol of 20% (p<0.001) (Table 2; Fig. 1), which was of a similar ab­
solute magnitude in all groups. However, an increase larger than 1 
mmol was only seen in two subjects of the E2/2 group. Two subjects 
(apo E phenotype E3/2 and E4/3) showed hardly any change in serum 
cholesterol by the diet. No significant correlation was found between 
the pre-diet cholesterol and the percentual increase in serum chol­
esterol. The major part of the change in total cholesterol could be 
ascribed to an increase in LDL cholesterol (p<0.001), which was simi­
lar in all groups. 
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.195 112 136 Í9_0 Δ'/. 
21 4 28 2 7 5 7 7 Δ У. 
Fig. 1 Individual changes of serum cholesterol and lipoprotein-
cholesterol concentrations in normolipidemic subjects by the 
cholesterol-rich diet. 
The percentual change in LDL-cholesterol by the diet (Fig. 2) corre­
lated inversely with the pre-diet value (r=-0.59; p<0.05), which cor­
responds to the larger relative increase (49%) in the E2/2 subjects. 
HDL-cholesterol rose significantly (p<0.Q01) with the highest increase 
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• E 3/3 
o E 3/2 
* E 4M-3 
α E 2/2 
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A 
• * 
D 0 
О 
* 
Τ А-Г« 1 ' 
1 3 5 
mmol/l 
Fig. 2 Percentual change in LDL-cholesterol concentration after the 
cholesterol-rich diet in relation with the basal level. 
in the E3/3 and E3/2 groups (21% and 2850, respectively). Serum trigly­
cerides remained unchanged, except in two E2/2 subjecta, who showed an 
increase of 2055 and 405», respectively, at the end of the high chol­
esterol diet. VLDL+IDL-cholesterol showed also a mean increase of 2255 
(p<0.05), which was most pronounced in the E2/2 group (555í). The 
E4A-3 subjects did not show any change. Only in the E2/2 subjects 
there was a riae in VLDL+IDL-triglycerides of 295Í. In the E2/2 group 
an increase of the total remnant concentration as estimated by the 
cholesterol concentration in both the heparin bound and the Sf 20-100 
fraction was found to be 6455 and 3655, respectively, whereas there was 
hardly any change in the concentration of remnants in the other pheno-
type groups. The cholesterol-rich diet caused a significant increase 
in serum apo В of 1855 in the total group (p<0.001) with the largest 
absolute and relative (4555) change in the E2/2 subjects. Apo E did not 
change in any of the phenotype groups. Comparing the E3/3 and the E3/2 
60-
40-
20-
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subjects with the E4/4-3 subjects no significant differences in 
dietary response with regard to all above mentioned parameters were 
found. In table 3 the relative amounts of cholesterol in the various 
lipoprotein fractions are given. 
Table 3 Distribution of cholesterol in the various lipoprotein 
fractions before (A) and after (B) the cholesterol-rich 
diet, expressed in % of serum chol, in E3/3, E3/2, E4/4-3 
and E2/2 subjects. 
VLDL+IDL-chol 
HDL-chol 
LDL-chol 
Diet 
A 
В 
A 
В 
A 
В 
E 3/3 
(n=3) 
% 
θ.7+4.1 
9.2+3.0 
27.2+6.5 
27.3+5.7 
64.1+4.0 
63.7+3.θ 
E 3/2 
(n=3) 
% 
13.2+4.5 
12.3+2.0 
25.5+7.1 
27.0+5.9 
61.4+3.0 
60.6+4.5 
E4/4-3 
(n=5) 
% 
9.8+2.5 
8.8+2.6 
25.8+3.6 
24.4+3.9 
66.4+7.7 
65.6+3.0 
E 2/2 
(n=3) 
% 
24.6+3.5 
27.1+2.1 
37.9+7.3 
30.1+3.1 
39.0+1.6 
42.9+4.3 
The E2/2 group had relatively more cholesterol in the VLDL+IDL and 
less in the LDL fraction compared to the other groups. After the chol­
esterol-rich diet the percentual distribution over the several lipo­
proteins seemed to change only in the E2/2 subjects, showing an in­
crease in both the VLDL+IDL and LDL fractions and a decrease in the 
HDL fraction. 
Changes in serun lipids, lipoproteins and retinyl palnitate by a fat 
load 
The highest triglyceride concentration (Fig. 3) after the arbitrarily 
chosen 4 hr time interval was demonstrated in the E2/2 subjects. 8 Hr 
after the fat load serum triglycerides had returned to initial levels 
in all groups. 
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o E 2/2 
• E 3/3 
o E 3/2 
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Fig. 3 Mean levels (+ SEM) of serum triglycerides before and after a 
fat load in normolipidemic subjects with various apo E pheno-
types. 
There was a small increase (5-8!«) in total cholesterol at 4 and θ hr 
in all groups, except in the E4/4-3 group (Table 4). In all groups 
there was an increase in the mean chylomicron-cholesterol concentra­
tion up to 8 hr. The increase in chylomicron-triglycerides was similar 
to the total triglyceride response. In all but the E3/2 group, there 
was an increase in VLDL+IOL-cholesterol, which was largest in the E2/2 
group and sustained up to 8 hr. There were no changes in the heparin-
Sepharose fractions and HDL cholesterol. In all groups the changes in 
LDL-cholesterol were very small. After 24 hr all the above-mentioned 
parameters had returned to basal values. 
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Table 4 Mean levels of serum cholesterol and lipoprotein cholesterol 
(mmol/L +SD) prior to and at 4, В and 24 hr after an oral 
fat load (50 g fat/m* + 2 egg yolks) in E3/3, E3/2, E4/4-3 
and E2/2 subjects. 
c h y l . c h o l 
VLDL+IDL-chol 
HDL-chol 
LDL-chol 
serum c h o l 
t ime 
0 
4 
θ 
24 
0 
4 
θ 
24 
0 
4 
В 
24 
0 
4 
В 
24 
0 
4 
θ 
24 
hr 
hr 
hr 
hr 
hr 
hr 
hr 
hr 
hr 
hr 
hr 
hr 
hr 
hr 
hr 
E3/3 
(n=3) 
0.0740.05 
0.16+0.09 
О.ІбчО.О? 
0.16+0.06 
0.43+0.17 
0.56+0.1 В 
0.50+0.23 
0.32+0.08 
1.34+0.14 
1.26+0.22 
1.36+0.16 
1.41+0.14 
3.35+0.74 
3.56+0.93 
3.32+0.93 
3.48+0.94 
5.08+0.81 
5.48+1.00 
5.42+0.81 
5.40+1.15 
E3/2 
(n=3) 
0.04+0.01 
0.12+0.03 
0.14+0.04 
0.11+0.02 
0.54+0.21 
0.55+0.24 
0.48+0.25 
0.36+0.10 
1.44+0.60 
1.44+0.66 
1.49+0.61 
1.48+0.59 
3.4540.93 
3.76+0.91 
3.65+1.17 
3.71+1.15 
5.40+1.43 
5.80+1.65 
5.85+1.55 
5.59+1.50 
E4/4-3 
(n=5> 
0.06+O.05 
0.15+0.04 
0.13+0.05 
0.09+0.05 
0.4340.14 
0.61+0.16 
0.39+0.15 
0.31+0.09 
1.25+0.23 
1.18+0.15 
1.26+0.25 
1.30+0.21 
3.32+0.54 
3.35+0.65 
3.30+0.57 
3.41+0.50 
5.17+0.85 
5.26+0.84 
5.10+0.83 
5.12+0.67 
E2/2 
(n=3) 
0.13+0.09 
0.23+0.09 
0.19+0.05 
0.12^0.08 
0.8140.27 
1.14+0.01 
1.1140.25 
0.88+0.09 
1.15+0.13 
1.10+0.16 
1.15+0.17 
1.12+0.12 
1.6840.54 
1.64+0.58 
1.5240.36 
1.75+0.59 
3.83+0.54 
4.07+0.83 
3.98+0.54 
3.94+0.74 
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In all groups a similar increase of chylomicron-retinyl palmitate (RP) 
was found at 4 hr after the fat load (Fig. 4), followed by a rapid de­
crease in the E3/3 and 4/4-3 groups and an intermediate decrease in 
the E3/2 group. The E2/2 group, however, showed a continuing rise 
after 4 hr till В hr. 24 Hr later the chylomicron-RP concentration was 
still considerably increased in two E2/2 subjects. 
chylomicron-ΚΡΙμπιοΙ/Ι) -heparin unbound-RP(umol/ll heparin bound-ΡΡΙμιποΙ/Ι) ι 
α E 2/2 
τ · E 3/Э 
Fig. 4 Mean levels (± SEM) of the retinyl palmitate (RP) concentra­
tions before and after a fat load in normolipidemic subjects 
with various apo E phenotypes 
The concentrations of hepann-unbound and bound RP after the fat load 
parallelled those of chylomicron-RP. The E3/2 subjects showed a normal 
RP response in the heparin bound fraction (Fig. 4), which is regarded 
to represent the remnant fraction. 
DISCUSSION 
This study was conducted to investigate a possible role of the apo E 
polymorphism in the receptor mediated regulation of lipoprotein levels 
during a cholesterol-nch diet. We chose to start in all subjects with 
a diet low in cholesterol and enriched in polyunsaturated fat (P/S 
0.7) to obtain a maximal cholesterol response by the cholesterol-nch 
diet. Since the amount of saturated fat may be as important as dietary 
cholesterol in increasing serum cholesterol levels (26), the P/S ratio 
of the high cholesterol diet was kept at 0.2. 
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By this diet average increments were found in serum cholesterol, 
VLDL+IDL-cholesterol, LDL and HDL-cholesterol, which were comparable 
with other studies, performed under similar conditions (18,26-28). 
Although the absolute changes in serum cholesterol and LDL-cholesterol 
were overall the same in the four apo E phenotype groups, yet in the 
E2/2 group the largest percentual changes were demonstrated (36 and 
49Ä, respectively). In the E2/2 subjects a consistent rise in 
VLDL+IDL-cholesterol was found, which was mainly caused by an increase 
of the remnant concentration (heparin-sepharose bound cholesterol; 
Table 2; Fig. 1). Furthermore, they had increased levels of triglycer-
ides in serum and in the VLDL+IDL fraction (Table 2) and of Sf >100 
cholesterol (results not shown) after the diet, possibly caused by an 
impaired removal of chylomicron remnants. 
The low LDL-cholesterol levels in E2/2 subjects under regular dietary 
conditions are supposed to be the result of an upregulated B,E recep-
tor system (9,15). This is thought to be caused by a decreased hepatic 
uptake of chylomicron and VLDL remnants. Under similar dietary condi-
tions as in this study, Mistry et al. (17) reported a reduction in B,E 
receptor activity of 745Ó. Therefore, there may be two explanations for 
the unexpected large relative changes in LDL-cholesterol in response 
to the diet in the E2/2 subjects. First, their B,E receptor system 
might be more down regulated by the cholesterol-rich diet than in sub-
jects with other phenotypes. A second possibility is, that more VLDL 
particles remain in the circulation and are ultimately converted to 
LDL by lipolytic processes, because of a delayed removal or increased 
production of VLDL particles. However, apo E-2 was found to be very 
ineffective in stimulating the lipolytic processing of intermediate 
density lipoproteins (IDL) to LDL in vitro (29). 
Gregg et al. (9) found kinetic differences between apo E-4 and E-3. It 
was speculated that apo E-4 may be more effective in mediating the 
hepatic uptake of remnants because of its shorter residence time in 
plasma. As a result of the faster catabolism of E-4 (by the apo E re-
ceptor) a down regulation of the B,E receptors and an increase in the 
conversion of VLDL remnants to LDL would occur especially in homozy-
gous E-4 subjects. Extending these findings to our study one could 
speculate that subjects with the Е4/4-Э phenotype have already a down-
regulated B,E receptor system at the start of the cholesterol-rich 
diet, so that minor changes in VLDL+IDL-cholesterol and LDL-cholester-
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ol would occur compared to the other phenotypes, except E2/2. This, 
however, was not the case neither in the two E4/4 nor in two of the 
three E4/3 subjects. Comparing the combined results of the E3/3 and 
the E3/2 subjects with those in the E4/4-3 subjects no significant 
differences were found. Neither in a previous study after a fat load 
with cream (19), nor in this study a partial removal defect of rem-
nants was found in heterozygous E-2 subjects. 
"Hypo"- and "hyperresponders" to a cholesterol-rich diet have been 
distinguished due to large inter-individual differences (IB,30). Yet 
the intra-individual reproducibility of the response to dietary chol-
esterol seems to be poor (28). Although this concept is still not well 
defined, in our study there were two hypo-responders (one with apo E 
phenotype E4/3 and one with E3/2), whereas all others could be classi-
fied as hyperresponders. So, except possibly in E2/2 subjects, the 
apo E polymorphism does not correlate with the degree of response to 
dietary cholesterol. In addition, we studied the effects of a high sa-
turated fat and cholesterol load (cream + 2 egg yolks) on the clearan-
ce of chylomicron remnants and the levels of various lipoproteins 
during 24 hours. There were only minor changes in total cholesterol 
and chylomicron-cholesterol, VLDL+IDL-cholesterol and LDL-cholester-
ol. Of interest, however, was that total cholesterol and LDL-chol-
esterol in the E4/4-3 group remained very constant throughout the ex-
periment, whereas all other groups showed a small increase (except in 
LDL-cholesterol in the E2/2 subjects). This finding is compatible with 
a maximal down-regulated B,E receptor system in the E4/4-3 subjects as 
mentioned above. 
The patterns of the RP curves of the chylomicron and the heparin un-
bound and bound fractions resembled strongly those in our previous 
study (19) although the subjects in that study were on their habitual 
diet and no egg yolks were added to the cream. In our opinion these 
results offer further indications that the uptake of chylomicron rem-
nants is mediated by specific (apo E) receptors, which are not in-
fluenced by metabolic derangements (31). Only in the E2/2 subjects 
slightly higher concentrations of RP in the chylomicron and in the 
heparin-sepharose fractions were observed than in our previous study. 
Presumably this was caused by an increase in the chylomicron remnant 
pool by the cholesterol-rich diet together with the presence of the 
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defective apo E-2 isoform on these particles. 
In conclusion, this study indicates that in normolipidemic subjects 
only the apo E2/2 phenotype seems to influence the response to a chol-
esterol-rich high fat diet in several lipoprotein classes. Therefore, 
such a diet may increase the atherosclerotic risk in these subjects 
(32) by increasing the amount of remnants in the circulation. Hetero-
zygous E-2 subjects as well as subjects with the E4/4 or E4/3 pheno-
type are indistinguishable in their response to dietary cholesterol 
and fat (16) from E3/3 subjects. The finding that the clearance of 
chylomicron remnants is not affected seriously by the cholesterol-rich 
diet, except in E2/2 subjects, is consistent with the view that chylo-
micron remnants are taken up independently of the B,E receptor system. 
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CHAPTER θ 
GENERAL DISCUSSION 
GENERAL DISCUSSION 
In this study we investigated whether the apo E polymorphism contri­
butes to the risk for atherosclerotic disease and whether it is asso­
ciated with hyperlipoproteinemia. Since the apo E isoproteins may 
exert different effects upon the metabolism of tnglycende-rich lipo­
proteins, several dietary experiments were performed in normolipidemic 
volunteers with various apo E phenotypes, to look for possible differ­
ences in the catabolism of remnants between these subjects. 
Because the ratio VLDL-cholesterol/serum triglycerides, which is com­
monly used as a measure for the relative amount of remnants, was con­
sidered not accurate enough to answer the questions in a part of our 
studies, we first validated hepann-sepharose affinity chromatography 
(1,2) as a more precise method to estimate the concentration of rem­
nants (Chapter 5). By this technique particles in the VLDL-density 
range, enriched in cholesterol and apo E, appeared to be bound by the 
column. With agarose electrophoresis it was found, that the heparin 
bound fraction showed a mobility intermediate between the β and pre-ß 
position. Lipoprotein particles with these characteristics correspond 
with remnants. Although hepann-sepharose chromatography or any other 
method does not result in a complete separation of remnants from 
nascent lipoproteins in the VLDL-density range, the concentration of 
cholesterol in the heparin bound fraction appeared to be the most use-
ful and best available estimate of the remnant concentration. The 
cholesterol concentration in the sf 20-100 fraction, obtained by 
cumulative rate ultracentrifugation (3), agreed well with the concen-
tration of heparin bound cholesterol, but this determination was too 
laborious for the purpose of these studies. 
The polymorphism of apo E in relation to cardiovascular disease was 
studied in 145 patients with angiographically proven coronary artery 
disease (CAD; Chapter 2) and in 76 patients with peripheral vascular 
disease (PVD; Chapter 3). In these conditions the frequency of the E-2 
homozygous and E-2 heterozygous apo E phenotypes was not significantly 
increased compared to controls without clinical signs of vascular dis-
ease. The lack of a significant difference could be due to the rela-
tive small number of patienta and controls; in addition it is uncer-
tain whether the control subjects were free of atherosclerosis, since 
they were not examined angiographically. However, our results in 
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patienta with coronary artery disease confirm earlier studies by 
Menzel et al. (3) and Utermann et al. (4) in a more extensive group of 
patients; we disagree with Cumming et al. (6), who showed an increased 
frequency of phenotype E4/3 and a decreased frequency of E3/2 in sur-
vivors of myocardial infarction under 60 years of age. Menzel et al. 
(4) also compared patients with angiographically proven stenosis with 
those with a normal angiogram and found a higher frequency of the E3/2 
phenotype in the last group, showing a possible protective effect 
against atherosclerosis by the E3/2 phenotype, possibly due to a lower 
serin cholesterol in these subjects. So, none of these studies reveal-
ed one of the apo E phenotypes as an independent risk factor. 
In addition the relationship between the apo E polymorphism, the 
levels of serum lipoproteins and the atherosclerotic risk was investi-
gated in CAD and PVD patients (Chapter 2 and 3). In agreement with 
other studies (7,8) it was demonstrated by logistic regression analy-
sis (Chapter 2), that the presence of the apo E-2 allele was in gene-
ral accompanied by higher concentrations of serum triglycerides, 
VLDL+IDL-cholesterol, serum apo E and a higher ratio VLDL+IDL-chol-
esterol/serum triglycerides and lower concentrations of serum chol-
esterol and LDL-cholesterol, whereas the apo E-4 allele was found to 
increase LDL-cholesterol and to lower apo E levels. 
In the E-2 homozygous (CAD) and E-2 heterozygous CAD and PVD patients 
elevated levels of VLDL+IDL-cholesterol appeared to contribute to the 
risk for atherosclerosis, whereas in subjects with phenotypes E3/3, 
E4/3 and E4/4 cardiovascular disease was accompanied by increased 
LDL-cholesterol levels. According to the increments in the concentra-
tions of heparin bound cholesterol in E-2 heterozygous CAD and PVD 
patients in comparison to controls, remnants might play a role in 
these subjects as a risk factor for atherosclerosis. The high preva-
lence of both coronary and peripheral artery disease in patients with 
type III hyperlipoproteinemia (9,10) and also the increased concentra-
tions of IDL in two recent reports in patients with coronary artery 
disease (11,12) underline the assumption, that remnants, like LDL-
cholesterol, contribute to the development of atherosclerotic disease. 
In case of hyperlipoproteinemia heterozygosity for apo E-2 was in both 
the CAD and PVD patients always associated with hypertriglyceridemia 
(Type IV), whereas in the other phenotypes distinct forms of hyper-
lipoproteinemia occurred. In E-2 homozygous (CAD) and E-2 heterozygous 
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subjects the highest mean concentrations of remnants were observed. 
These findings are in agreement with the results described in Chapter 
4, where in hyperlipidemic patients, classified as type IV, a ratio 
VLDL-cholesterol/serum triglycerides above 0.5 (indicating a relative 
increase in remnants) was accompanied by heterozygosity for apo E-2 in 
about 50% of the cases. 
Logistic regression analysis revealed, that serum apo E had no signi­
ficant contribution to the prediction of either CAD or PVD. However, 
other apolipoproteins, such as LDL apo В and serum apo A-I were im­
portant in the prediction of cardiovascular disease. Our results 
support the hypothesis of Avogaro et al. (13), that apolipoproteins 
are a better discriminator than serum or lipoprotein lipids between 
subjects with atherosclerotic disease and controls. 
Furthermore, we studied patients with well classified forms of hyper­
lipoproteinemia, and found that the apo E polymorphism was associated 
with some of these forms. In keeping with our diagnostic criteria, all 
type III hyperlipoproteinemic patients were homozygous for apo E-2. 
Apart from the relationship between homozygosity for apo E-2 and Type 
III, there was also an association between E-2 heterozygous phenotypes 
and Type IV (22Й) and V hyperlipoproteinemia (355ί). A similar relation 
was observed in hypertriglyceridemic CAD and PVD patients (Chapter 2 
and 3). In earlier studies also an association of the apo E-2 allele 
with hypertriglyceridemic states was found (14,15); however, in con­
trast to these studies, we observed no significant relation of the apo 
E-4 allele with hypercholesterolemia (Type Ila) or severe hypertrigly­
ceridemia (16) (Type V). So, the studies in Chapter 2, 3 and 4 indi­
cate, that by the presence of type IV in E-2 heterozygous subjects a 
partial removal defect of remnants becomes overt, due to VLDL overpro­
duction. As discussed above elevated concentrations of remnants could 
imply an increased risk for atherosclerosis in these subjects. 
In the second part of this thesis (Chapters 5, 6 and 7) studies of the 
role of the apo E polymorphism in lipoprotein metabolism are described 
in normolipidemic subjects with special emphasis on the catabolism of 
remnants under different metabolic conditions. By challenging the apo 
B,E and E receptors with increased amounts of remnants, a (partial) 
removal defect may be revealed in E-2 homozygous and E-2 heterozygous 
subjects. Previously, Zilversmit (17) hypothesized that postprandial 
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accumulation of chylomicron remnants, in spite of normolipidemia under 
fasting conditions, may raise the risk for atherosclerotic disease. 
- Up to 8 hr after a fat load (Chapter 5) the disappearance of chylo-
micron remnants, using retinyl palmitate as a marker, was markedly 
delayed in E-2 homozygous subjects, but not in E-2 heterozygous sub-
jects. 
- Induction of the VLDL synthesis by a diet with a high carbohydrate 
content and by alcohol (Chapter 6) caused in all subjects a small, but 
similar increase in the concentration of remnants in the d<1.019 g/ml 
fraction. In E-2 homozygous subjects the clearance of chylomicron rem-
nants was improved at the end of the diet in comparison to basal con-
ditions, probably due to the low fat content of the diet and conse-
quently a smaller pool of circulating chylomicron remnants. 
- Normolipidemic E-2 homozygous subjects responded differently to a 
high cholesterol (1800 mg) and high saturated fat (P/S=0.2) diet com-
pared with subjects with other phenotypes by showing the largest abso-
lute and percentual increments in total cholesterol and an accumula-
tion of remnants (Chapter 7). The rise in LDL-cholesterol was not re-
lated to the apo E phenotype. So in this study, there was no evidence 
for a role of the apo E isoproteina in the regulation of the number of 
3,E receptors. Recently it was proposed by Utermann (18), that E-2 
homozygous subjects may have an upregulated B,E receptor system com-
pared to the other phenotypes, due to the defective uptake of chol-
esterol enriched remnants of dietary origine in the liver. In addition 
Gregg et al. (19) found that apo E-4 was catabolized more rapidly than 
apo E-3 and E-2. They speculated, that the enhanced catabolism of E-4 
containing triglyceride-rich lipoproteins causes a down regulation of 
B,E receptors, which would explain the higher LDL-cholesterol levels 
in E4/4 subjects compared to those with the other apo E phenotypes. 
LDL-turnover studies in E2/2 and E4/4 subjects are needed to prove the 
reliability of this postulation. 
These metabolic experiments indicate that in normolipidemic E-2 homo-
zygous subjects the clearance of remnants may become critical under 
several dietary conditions except during a high carbohydrate low fat 
diet. On the contrary, this was not the case in normolipidemic E-2 
heterozygous subjects. 
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In summary: according to our studies, the question, whether the apo E 
polymorphism is a risk factor in coronary and peripheral vascular dis-
eases has to be answered negatively. Nevertheless, the apo E phenotype 
can affect the concentrations of VLDL remnants and LDL, especially in 
the presence of hyperlipoproteinemia (Type III and IV) and may there-
fore determine in the individual which lipoprotein is important for 
atherosclerosis. Because of this relationship between the apo E poly-
morphism and lipoprotein levels, it seems necessary to make a differ-
entiation in the population with regard to the risk for atherosclero-
sis. Thus, in E-2 homozygous and E-2 heterozygous subjects, remnants 
might be the predominant atherogenic lipoprotein, whereas in other 
phenotypes this is LDL. It is conceivable that food habits play an 
additional role in this respect. 
In spite of elevated concentrations of atherogenic remnants in the 
fasting state and a postprandial delay in the removal of chylomicron 
remnants, no increased prevalence of the E2/2 phenotype was observed 
in coronary and peripheral artery disease. According to our dietary 
experiments and with reference to the hypothesis of Zilversmit (17), 
it is advisable to give dietary instructions to normolipidemic E-2 
homozygous subjects. In practice, first the normolipidemic E-2 homo-
zygous relatives of Type III hyperlipidemic patients have to be con-
sidered. Taking into account our results during a high-carbohydrate 
low fat diet, fat and caloric restriction seems recommendable to 
prevent in these subjects the development of Type III hyperlipopro-
teinemia and perhaps of atherosclerotic disease in the long run. 
Nevertheless, as far as atherosclerotic risk is concerned, one has to 
keep in mind that, due to its relative low prevalence, the E2/2 pheno-
type (IS) plays only a modest role in the general population. 
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SAMENVATTING 
Cholesterol en triglyceriden vormen tezamen met fosfolipiden en apo-
protelnen de bouwstenen voor de lipoproteïnen in het plasma, die op 
grond van hun dichtheid bij ultracentrifugatie worden onderscheiden in 
achtereenvolgens: chylomicrons, very low-denaity lipoproteïnen (VLDL), 
intermediate density lipoproteïnen (IDL), low-density lipoproteïnen 
(LDL) en high-density lipoproteïnen (HDL). Van chylomicrons naar LDL 
is er een toename in cholesterol(esters) en eiwit en een afname in 
triglyceriden. De apoproteïnen, die samen met fosfolipiden en choles-
terol de mantel vormen van lipoproteïnedeeltjes, zijn van belang bij 
het transcellulaire transport van lipoproteïnen (apo В en apo E) of 
dienen als cofactor voor lipolytische enzymen (apo A-I en apo C-II). 
Centraal in dit proefschrift staat het apo E, dat vooral aanwezig is 
in de triglyceriderijke lipoproteïnen: de chylomicrons, die in de darm 
gesynthetiseerde triglyceriden transporteren en VLDL, die in de lever 
worden gevormd. Hydrolyse van deze partikels in de bloedbaan o.i.v. 
lipoprotéine lipase leidt tot het ontstaan van zogenaamde remnants. 
Apo E speelt een belangrijke rol bij de receptor-afhankelijke opname 
en afbraak van remnants in de levercel door een interactie aan te gaan 
met de remnant-(apo E)-receptoren of de LDL-(apo 8,E)-receptoren. Ten 
dele worden remnants niet direct opgenomen, doch eerst omgezet in LDL, 
die uiteindelijk via de apo B,E-receptoren worden opgenomen in de cel-
len. 
Door middel van isoelectric focusing kan een drietal apo E isoproteï-
nen worden onderscheiden, apo E-2, E-3 en E-4. De verschillen in iso-
electrisch punt worden veroorzaakt doordat op twee plaatsen in het apo 
E molecuul de aminozuursamenstelling kan variëren. De vorming van deze 
apo E isoproteïnen wordt genetisch bepaald door een polymorf gen met 3 
allelen (e2, e3 en e4). Op basis van dit genetisch polymorfisme en de 
aanwezigheid van 2 apo E genen per lichaamscel, is een zestal apo E 
fenotypen te onderscheiden: E2/2, E3/3, E4/4 (homozygoten) en E3/2, 
E4/3 en E4/2 (heterozygoten). Omdat het apo E allei еЗ bij ca. 70% van 
de mensen voorkomt, komen de hiervan afgeleide fenotypen E3/3 (555í), 
E4/3 (25Só) en E3/2 (15X) het meest voor in de populatie. De overige 
fenotypen (E2/2, E4/4 en E4/2) worden in totaal slechts bij 5% van de 
mensen gevonden. 
Studies met betrekking tot de binding van de drie apo E isoproteïnen 
aan B,E receptoren van fibroblasten hebben uitgewezen, dat apo E-2 
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niet of nauwelijks wordt herkend door de lipoproteïne-receptoren, in 
tegenstelling tot apo E-3 en E-4, die normaal worden gebonden. 
De meeste mensen met het fenotype E2/2, dat in een frequentie van 1X 
voorkomt, hebben, ondanks normale waarden voor cholesterol en trigly-
ceriden, verhoogde remnant concentraties in het bloed. Echter 1-45» van 
de mensen met E2/2 heeft verhoogde lipidenwaarden en is lijdende aan 
een type III hyperlipoproteïnemie. Zowel bij deze autosomaal recessief 
overervende vetstofwisselingsziekte als bij normolipidemische E-2 
homozygoten, is in de lever de receptor-afhankelijke opname en afbraak 
van remnants gestoord door de aanwezigheid van het abnormale E-2 iso-
proteïne. Er ontstaat een hyperlipidemie als naast het genetisch be-
paalde klaringsdefect van remnants ook nog een overproductie van VLDL 
bestaat, zoals bij een erfelijk bepaalde aanleg voor hyperlipidemie en 
bij overgewicht, diabetes mellitus, overmatig alcoholgebruik of hypo-
thyreoidie. De opeenhoping van remnants in de circulatie bij type III 
patiënten geeft een grote kans op athérosclérose. Met name het optre-
den van perifeer vaatlijden is een opvallend verschijnsel. Wij vonden 
bij de 39 patiënten met deze vorm van hyperlipoproteïnemie, die in 
onze kliniek onderzocht werden, coronairlijden bij 38% en perifeer 
vaatlijden bij 46%. 
In dit proefschrift is nagegaan of het polymorfisme van apo E bij-
draagt tot de kans op coronair en perifeer vaatlijden naast andere be-
kende risicofactoren, zoals hyperlipidemie, roken, diabetes en hyper-
tensie. Hiertoe is in de eerste plaats een grote groep patiënten met 
bewezen vaatlijden vergeleken met een controlegroep. Voorts is bij een 
grote groep patiënten met hyperlipidemie de relatie onderzocht tussen 
het polymorfisme van apo E en het voorkomen van de diverse hyperlipo-
proteïnemieën. Met als uitgangsstelling dat het nadelige effect van 
apo E-2 op het metabolisme van remnants vooral tot uiting zal komen 
bij een verhoogd aanbod aan remnants werden tenslotte metabole belas-
tingsstudies verricht bij normolipidemische personen met de diverse 
apo E fenotypen om te zien of daardoor een ophoping van de atherogene 
remnants optreedt, die in de nuchtere toestand niet waarneembaar is. 
Uit de hoofdstukken 2 en 3 blijkt dat de apo E fenotypeverdeling bij 
patiënten met angiografisch aangetoond coronair en perifeer vaatlijden 
niet significant verschilt met die van een controlegroep zonder klini-
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sehe tekenen van vaatlijden. Wel bleek het apo E fenotype van invloed 
te zijn op de concentraties van serumlipiden, lipoproteïnen en apopro-
teinen. Bij E-Z homozygote en E-2 heterozygote patie'nten lijken vooral 
verhoogde VLDL+IDL-choleaterolconcentratіеэ en daaraan gekoppeld ver­
hoogde remnant concentraties bij te dragen tot de kans op coronair en 
perifeer vaatlijden. Bij patiënten met de fenotypen E3/3, Е4/3 en E4/4 
ligt de nadruk meer op LDL-cholesterol als risicofactor. 
Opvallend was verder, dat E-2 heterozygote patiënten met coronair en 
perifeer vaatlijden, in geval van een hyperlipidemie, stee'ds een 
hypertriglyceridemie (Type IV) hadden. Type IIa hyperlipoproteïnemie 
(hoog LDL-cholesterol) kwam alleen voor bij patiënten met de apo E 
fenotypen E3/3, E4/3 en E4A. 
Het totale apo E gehalte van het serum bleek geen voorspellende waarde 
te hebben ten aanzien van het optreden van coronair of perifeer vaat-
lijden. Dit was wel het geval met betrekking tot LDL apo В en serum 
apo A-I, die zelfs betere voorspellende parameters waren dan lipopro­
teïnen. Zoals reeds bekend uit de literatuur, was HDL-cholesterol ne-
gatief geassocieerd met coronairlijden en was VLDL-t-IDL-choleeterol po-
sitief gecorreleerd met perifeer vaatlijden. Overigens was perifeer 
vaatlijden zeer sterk geassocieerd met fors roken. Voorts bleek de 
aanwezigheid van het allei e2 gepaard te gaan met hogere concentraties 
van de serumtriglycenden, VLDL+IDL-cholesterol, serum apo E en een 
hogere VLDL+IDL-cholesterol/serum triglycende-ratio en lagere serum-
en LDL-cholesterolconcentraties ten opzichte van het gemiddelde van de 
totale controle- en patiëntenpopulatie. De aanwezigheid van apo E-4 
had een LDL-cholesterolverhogend effect en ging gepaard met lagere apo 
E-concentraties. 
In hoofdstuk 4 is de samenhang tussen het apo E polymorfisme en het 
voorkomen van hyperlipoproteïnemie onderzocht bij een grote groep van 
501 patiënten met een goed geklassificeerde hyperlipoproteïnemie. Het 
apo E allei ε2 bleek, behalve met type III hyperlipoproteïnemie, ook 
enigszins geassocieerd te zijn met type IV en type V hyperlipopro-
teïnemie. Bij type IV patiënten ging een VLDL-cholesterol/serumtrigly-
ceride-ratio boven 0.5 in bijna 50% van de gevallen vergezeld van 
heterozygotie voor apo E-2. Het ε4 allei bleek geen significante rela­
tie te vertonen met hypercholesterolemie (type II) of type V hyperli­
poproteïnemie, zoals wel door andere onderzoekers is beweerd. 
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In de hoofdstukken 5 t/m 7 is de rol van het apo E polymorfisme bestu-
deerd in het lipoproteïnemetabolisme onder verschillende metabole con-
dities. In hoofdstuk 5 zijn de resultaten weergegeven van vetbelas-
tingstesten met room, die gedurende 8 uur werden uitgevoerd bij normo-
lipidemische vrijwilligers met verschillende apo E fenotypen. Om de 
verdwijning van chylomicron remnants te kunnen vervolgen werd retinyl 
palmitaat als "marker" toegepast, gebruik makend van het feit dat dit 
vit. A-derivaat tijdens de lipolyse in de kern van de chylomicrons 
blijft tot de uiteindelijke opname in de lever. Acht uur na inname van 
de room werd een sterk vertraagde verdwijning van chylomicron remnants 
gevonden bij de E-2 homozygoten. De E-2 heterozygoten vertoonden 
echter een zelfde klaring als de proefpersonen met de overige apo E 
fenotypen. 
De resultaten in hoofdstuk 6 laten zien dat, na vergroting van de 
VLDL-synthese door middel van een koolhydraatrijk dieet met extra 
alcohol gedurende 7 dagen, er in alle fenotype groepen een geringe 
toename van remnants was. Ook tijdens dit dieet werd er geen (par-
tieel) defect gevonden in de afbraak van remnants bij E-2 heterozygo-
ten. 
In hoofdstuk 7 zijn de resultaten weergegeven van een cholesterolrijk 
(1800 mg) dieet met een hoog verzadigd vetgehalte (P/S ratio = 0.2) 
bij normolipidemische vrijwilligers met verschillende apo E fenoty-
pen. E-2 homozygoten lieten de grootste absolute en percentuele veran-
deringen zien in serumcholesterol. Bovendien was er bij hen sprake van 
een toename in de concentratie van remnants in tegenstelling tot 
vrijwilligers met de overige fenotypen, de E-2 heterozygoten incluis. 
De gemiddelde toename van het LDL-cholesterol was in alle fenotype 
groepen hetzelfde, zodat in deze studie geen steun werd gevonden voor 
de hypothese, opgesteld door andere onderzoekers, dat apo E isoproteï-
nen een rol spelen bij de regulering van het aantal B,E receptoren en 
dientengevolge van de concentratie van LDL-cholesterol. 
Resumerend kan op grond van de studies in dit proefschrift gesteld 
worden, dat het apo E polymorfisme bij normolipidemische personen niet 
significant bijdraagt tot het risico op hart- en vaatziekten. Middels 
effecten op de concentraties van VLDL+IDL en LDL, kan het apo E poly-
morfisme vooral in aanwezigheid van een hyperlipoproteïnemie (т.п. 
type IV) het atherosclerose-risico beïnvloeden. Lipoproteine remnants 
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lijken in dit verband van belang te zijn bij E-2 homozygoten en E-2 
heterozygoten, terwijl bij de andere apo E fenotypen het LDL-choleste-
rol het overwegend atherogene lipoprotéine is. 
Afhankelijk van hun dieetgewoonten, kunnen normolipidemische E-2 homo-
zygoten een verhoogde kans op athérosclérose hebben doordat bij hen, 
vooral na vetrijke maaltijden, remnants langdurig blijven circuleren. 
Waarschijnlijk zijn dieetadviezen voor deze personen dus belangrijk. 
Anderzijds hebben zij een laag LDL-cholesterol, wat weer een gunstige 
factor is ten aanzien van de kans op athérosclérose. Bovendien is de 
prevalentie van de E-2-hofflozygotie slechts 1%, zodat dit kwantitatief 
geen belangrijke risicofactor voor athérosclérose in de bevolking 
vormt. Bij normolipidemische E-2 heterozygoten zijn er ook na belas-
ting van het klaringsmechanisme geen aanwijzingen voor een (partieel) 
gestoorde afbraak van remnants. 
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De patiënten wil ik danken voor hun bereidwillige medewerking aan het 
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een speciale vermelding voor de wijze waarop zij hun afkeer van de 
soms zeer onaangename kost wisten te verbergen en zich stipt aan de 
dieetvoorschriften hielden. 
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De Nederlandse Hartstichting ben ik zeer erkentelijk voor de subsidie, 
die aan dit onderzoek is verleend in de jaren 1983-1986. 
Tenslotte dank ik Ans Ruesen voor de toewijding en zorg, besteed aan 
het typen en drukklaar maken van het manuscript. 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd geboren op 15 mei 1953 te 
1s-Hertogenbosch. In 1971 behaalde hij het einddiploma gymnasium-S aan 
het Sint Janslyceum in zijn woonplaats. Daarna studeerde hij genees-
kunde aan de Katholieke Universiteit te Nijmegen, waar hij in 1977 het 
doctoraalexamen en in 1979 het artsexamen aflegde. Aansluitend begon 
hij met zijn opleiding tot internist aan de Universiteitskliniek voor 
Inwendige Ziekten van het Sint Radboudziekenhuis te Nijmegen (oplei-
ders: Prof. Dr C.L.H. Majoor en Prof. Dr A. van 't Laar). Op 1 april 
1984 werd hij geregistreerd als internist. Vervolgens was hij werkzaam 
binnen de afdeling Algemene Interne Geneeskunde (Hoofd: Prof. Dr A. 
van 't Laar). Vanaf 1 september 1987 is hij als algemeen internist 
verbonden aan het St. Joseph Ziekenhuis te Veghel, tezamen met Mevr. 
J.B. Verhagen, H.E.A.M. van Glabbeek en Dr L.H. van Hulsteijn. Hij is 
getrouwd met Jenny de Keijzer. Zij hebben een zoon en een dochter, 
Sjoerd en Evelien. 
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STELLINGEN 
1. Het apo E polymorfisme kan niet als een onafhankelijke risicofac-
tor ten aanzien van coronair en perifeer vaat lijden worden aange-
merkt. 
(dit proefschrift) 
2. Bij E-2 homozygote en E-2 heterozygote patiënten met atherosclero-
tisch vaatlijden zijn lipoproteïne-remnants de overwegende athero-
gene lipoproteïnen, terwijl dit bij de andere apo E fenotypen de 
low-density lipoproteïnen zijn. 
(dit proefschrift) 
3. Ongeveer 50л van de type IV patiënten met een ratio VLDL-choleste-
rol/serum TG boven 0.5 is heterozygoot voor het ε2 allei. De ver­
hoogde remnantconcentraties bij deze categorie patiënten geven een 
verhoogde kans op athérosclérose. 
(dit proefschrift) 
4. Normolipidemische personen met het fenotype E2/2 breken na een 
vetbelasting chylomicron-remnants vertraagd af, in tegenstelling 
tot personen met het E-2 heterozygote fenotype. 
(dit proefschrift) 
5. Tijdens een cholesterolnjk dieet (1800 mg cholesterol/dag; P/S = 
0.2) is de stijging van low-density lipoprotéine-cholestérol niet 
gerelateerd met het apo E fenotype. De apo E isoproteinen spelen 
derhalve geen wezenlijke rol in de regulatie van het B,E receptor-
systeem. 
(dit proefschrift) 
6. Het is aan te bevelen normolipidemische familieleden van type III 
patiënten met het E2/2 fenotype een vet- en calorie-beperkt dieet 
te adviseren ter preventie van een type III hyperlipoproteinemie 
en atherosclerotisch vaatlijden op de langere duur. 
(dit proefschrift) 

7. Ofschoon het ontbreken van een gunstig effect van antihypertensie-
ve behandeling op de incidentie van coronaire vaatziekten mogelijk 
een gevolg is van een negatieve beïnvloeding van de serumlipiden, 
is het onjuist, als men zich bij de keuze van een antihypertensi-
vum vooral laat leiden door effecten op metabole parameters en 
niet de mate van bloeddrukdaling en de subjectieve bijwerkingen 
laat meewegen. 
PP Koopmans en PMJ Stuyt, Ned Tijdschr Geneeskd 1987;131:1560-
1564. 
8. Patiënten met een hypercholesterolemie mogen alleen met galzuur-
bindende harsen behandeld worden, als het triglycendengehalte 
niet of slechts licht verhoogd is. 
9. Stoffen afkomstig uit monocyten, waaronder interleukine-1, spelen 
een belangrijke rol met betrekking tot de afname van de albumine-
synthese in de lever tijdens ontstekingsprocessen. 
HJ Moshage e.a. J Clin Invest 19Θ7;79:1635-1641. 
10. Spreken over remissie-inducerende geneesmiddelen bij de behande­
ling van rheumatoide arthritis is onjuist. Vroegtijdige behande­
ling kan een symptomatische verbetering geven in de beginfase, 
maar de prognose op langere termijn is matig. 
DL Scott e.a. Lancet 1987;ι:1108-1111. 
11. In geval van post-hepatische obstructie ten gevolge van een malig­
ne proces verdient het primair inbrengen van een endoprothese 
langs endoscopische weg de voorkeur boven de percutané methode. 
AG Speer e.a. Lancet 1987;ii:57-60. 
12. De wijze waarop momenteel Ibuprofen bij de consument wordt aange-
prezen als een nieuwe en vrij verkrijgbare pijnstiller dient als 
uiterst misleidend te worden bestempeld. 
13. De gewelddadigheid in en rond voetbalstadions vraagt om heroverwe-
ging van historisch gereedschap, zoals de schandpaal. De aanwezige 
doelpalen zouden deze functie kunnen vervullen, terwijl de penal-
tystip en een hard opgepompt vijfje nuttige accessoires zouden 
zijn. 
14. Spoedige verwijdering van nucleaire wapens van dit continent zal 
ons hopelijk verlossen van afschrikwekkende termen als moratorium 
en dubbele nuloptie. 
Nijmegen, 6 November 1987 B.J. Brenninkmeijer. 


